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ABSTRACT
TAKING CLINICAL JUDGMENT OUT OF THE EQUATION: A CALL FOR THE
STANDARDIZATION OF MCI DIAGNOSTIC CRITERIA AND CONSTRUCTION
OF A MODEL TO PREDICT CONVERSION TO DEMENTIA
Adam Gerstenecker
June 26, 2014
Although the diagnostic criteria for mild cognitive impairment have evolved
considerably since their inception, they remain varied and able to be interpreted and
implemented in different ways depending on the judgment of the clinician. Because of
this issue, a wide range of incidence, prevalence, and conversion rates are found in the
research literature. Using data collected from 400 patients with amnestic mild cognitive
impairment, limitations inherent in current mild cognitive impairment diagnostic criteria
were addressed. First, using Alzheimer’s Disease Neuroimaging Initiative diagnostic
criteria, an equation was constructed to predict conversion from mild cognitive
impairment to dementia by analyzing the predictive ability of variables representative of
a number of categories (i.e., demographic, psychiatric, functional, biomarker, imaging,
and cognitive). This model accounted for over 60% of variance in conversion and
exhibited an area under the curve of 0.93. Then, separate models were constructed using
different applications of the current diagnostic criteria for mild cognitive impairment. As
expected, criteria utilizing a one standard deviation clinical cutoff on a measure of
delayed verbal recall in combination with the allowance for some functional change (i.e.,
iii

scores ≤5 on the Functional Activities Questionnaire) exhibited the greatest utility of any
combination of diagnostic criteria. Taken together, these results indicate that statistical
equations can be constructed to predict conversion from mild cognitive impairment to
dementia and be tailored for widespread clinical use. Moreover, these results show that
the standardization of current diagnostic criteria for mild cognitive impairment is clearly
needed.
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INTRODUCTION

Mary and the Diagnostic Process
Mary is a 67-year-old Caucasian woman whose family is concerned that she is
“having trouble with her memory.” Her daughter reports that Mary exhibits some
difficulty “keeping up” in conversations and recently “lost track of her hand” while
playing bridge. This was noted as especially distressing to Mary’s daughter because
Mary has been an avid bridge player for over 40 years and “quite the card shark.” In
contrast to his sister, Mary’s son reports that his mother’s memory is “no different from
other people [her] age.” When Mary is asked about her memory, she reports “it is just
fine.” Mary’s primary concern is “feeling depressed” and “not being able to stay asleep
at night because [she] worries too much.”
After completing a neuropsychological battery, Mary exhibited average
performance when compared to age- and education-matched peers on a test of general
cognitive functioning (25th percentile). No subscale scores fell more than 1.5 standard
deviations (SD) below the mean. However, on a more comprehensive test of memory,
Mary exhibited below average immediate (20th percentile) and delayed recall (15th
percentile). Mary’s family reports that she is completely independent in both higher- and
lower-order activities of daily living (ADL), but Mary was not administered a functional
measure as part of her neuropsychological evaluation. Given these observations, her
attending physician recommended she be diagnosed with mild cognitive impairment
1

(MCI) and prescribed Aricept (a medication designed to target memory function in older
adults). However, the neuropsychologist who administered the tests recommended she
be re-evaluated in 6-9 months after being treated for depression and anxiety.
Nevertheless, Mary was diagnosed with MCI, the diagnosis recorded in her medical
records, and her family educated about the diagnosis and increased risk MCI patients
have for progression to a dementia syndrome.
Study Purpose
The purpose of the current study is to demonstrate how MCI diagnostic criteria
are affected by a lack of standardization and clinical judgment. This issue will be
discussed in detail, and a potential solution proposed. This solution will take the form of
two statistical models: (1) a “screening” model designed to increase the standardization
of diagnostic criteria, and (2) a “conversion” model designed to fully remove clinical
judgment from the diagnostic process. The screening model will primarily be based upon
the most widely used and accepted MCI clinical diagnostic criteria. However, particular
emphasis will be given to decreasing the ambiguity of these criteria so they can be
applied in a consistent manner. For the conversion model, data from a full clinical and
medical evaluation will be used to construct a mathematical equation designed to identify
people at particular risk of converting from MCI to dementia. The proposed conversion
model will be based upon the combined predictive power of numerous factors including
neuropsychological performance, neuroimaging, biomarkers, behavioral abnormalities,
and functional ability.
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Mary’s Diagnosis and Clinical Judgment
Mary’s case illustrates the prominent role clinical judgment assumes in the
evaluation of older adults with suspected cognitive impairment. But, how can clinical
judgment play such a prominent role in a process so seemingly driven by data? The
answer is simple: statistical models of diagnostic prediction are not readily available to
professionals nor used by professionals when working with older adults. Consequently,
these professionals often rely on heuristics. In short, heuristics are mental tools based on
prior experience and knowledge that are used to reduce cognitive burden in decision
making and to allow for faster and often correct decisions (Shah & Oppenheimer, 2008).
However, by introducing personal heuristics into the decision-making process, personal
cognitive biases are also introduced and contribute to errors in judgment (Tversky &
Kahneman). Consequently, two clincians with the best interests of a patient in mind could
have quite different diagnostic impressions of the very same set of presenting symptoms.
For example, Mary’s physician frequently encounters patients whose families
report memory loss. More often than not, these patients have dementia or MCI. This
leads the physician to develop a heuristic about patients similar to Mary. Thus, when
Mary exhibited some minor impairment in memory, the heuristic developed by her
physician contributed to Mary being diagnosed with amnestic MCI. In contrast to the
physician, the neuropsychologist working with Mary frequently encounters patients
reporting clinically significant symptoms of depression and anxiety. More often than not,
these patients experience problems with memory and/or attention. Consequently, the
neuropsychologist developed a heuristic that borderline or mildly impaired memory may
be a byproduct of depression and not necessarily caused by a neurodegenerative disorder.
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As can be seen, both the physician and neuropsychologist utilized prior experience in
forming divergent viewpoints of Mary’s condition.
Clinical versus Statistical Judgment
The Legacy of Paul Meehl
The question of clinical versus statistical judgment was first brought to
prominence in 1954 after Paul Meehl published a book comparing the two methods.
Meehl classified clinical judgment as judgments based on the prior experience of a
human judge. On the other hand, human decision-making is eliminated in the statistical
method in favor of empirical relations between obtained data and the criterion. But,
basing decisions on a statistical model entails more than simply applying automated
decision rules just as programming computers entails more than mimicking clinical
judgment. The key point is that in order for a decision method to be considered
statistical, it must not only be automated but must also be based on empirically
established relationships (Dawes, Faust, & Meehl, 1989).
Since Meehl’s (1954) seminal publication, the number of investigations
examining clinical versus statistical judgment has grown to more than 150, and the results
remain consistently in favor of the statistical method. In the few studies in which a
preference for clinical judgment was noted, alterations to the statistics used in the
prediction equation had a tendency to tip the scales in favor of the statistical method
(Dawes, 2005). In sum, the role of clinical versus statistical judgment has been well
studied in psychology, and the evidence points to the clear superiority of the statistical
method (Dawes, Faust, & Meehl, 1989).

da. To c
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Clinical Versus Statistical Judgment in the Diagnosis of MCI
Returning to the diagnosis of Mary, it is apparent clinical judgment has led to two
contradictory hypotheses made by her attending physician and neuropsychologist: (1) that
she should be diagnosed with MCI because of her memory decrements and (2) that she
should not be diagnosed with MCI because her suboptimal memory may be a byproduct
of depression and anxiety. How such contradictory views can be formed has already
been discussed, but a solution not formally proposed. As will be outlined in the next
section of this paper, the lack of standardization of the existing diagnostic criteria needs
to be addressed before the development of a statistical model designed to predict
conversion from MCI to dementia.
Because of the ambiguity of diagnostic criteria, clinical judgment is heavily relied
upon when determinations about an MCI diagnosis are made. This leads to a number of
potential problems that affect both clinical practice and research studies: (1) people with
MCI will not receive treatment until more serious cognitive decline is exhibited, (2)
people will be misdiagnosed as having MCI and be given unnecessary treatment, (3)
samples included in research studies will be representative of different populations
leading to the decreased generalizability of the findings and how they relate to MCI, (4)
the prognosis of MCI patients remains unclear, and (5) reliable estimates of MCI
prevalence cannot be obtained. A statistical model can help in this regard. However,
before a discussion of MCI diagnostic criteria and the application of a statistical model
can take place, the concept of MCI as a predementia syndrome will be introduced.

5

Predementia: From “Normal” Cognition to Dementia
As the brain ages, many older adults experience changes in cognition. It is only
when changes exceed what is expected that normal cognition is thought to be
compromised. As many as 1 in 7 adults over the age of 71 are currently living with
dementia (Plassman et al., 2007), and this number may triple by the year 2050 with older
adults over the age of 85 being most affected (Hebert, Scherr, Bienias, Bennett, & Evans.,
2003). Although numerous different dementia syndromes have been identified,
Alzheimer’s disease (AD) is the most well-known and widely researched type of
dementia. But transition from normal cognition to AD is not a one-step process, and
“preclinical stages” (changes in the brain that occur prior to the onset of clinically
detectable symptoms) are thought to precede the disease and may last upwards of 20
years. Once these preclinical changes become associated with observable cognitive or
functional deficits, a predementia syndrome is said to be present. To date, a number of
predementia syndromes have been proposed, but relatively few have thoroughly
delineated research criteria that yield the opportunity for ongoing study and the
examination of rates of progression to dementia (Panza et al., 2005).
Mild Cognitive Impairment: The Evolution of a Diagnosis Reflects Limitations
Of all the terms used to describe predementia syndromes, the most well-known
and extensively researched is MCI. Simply stated, MCI is a term used to describe
cognitive decline that does not significantly interfere with daily functioning and,
therefore, does not meet criteria for dementia. Given this broad definition, the potential
exists for MCI to be a term that unifies all other terms used to classify predementia
syndromes and declines in cognition not associated with normal aging. However, this
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was not always the case as memory impairment was originally a necessary diagnostic
component. By having this stipulation, MCI was more reflective of a pre-AD stage than
a preclinical syndrome related to general cognitive impairment. Currently, MCI is no
longer conceptualized as a unitary construct dependent on memory impairment but a
syndrome with multiple subtypes: amnestic-MCI (aMCI); multiple domains, slightlyimpaired-MCI (mdMCI); and single, non-memory-domain-MCI (snMCI).
MCI Conceptualized: Contributions of the New York University Group
MCI was originally conceptualized by a research group from New York
University in 1991 (Flicker, Ferris, & Reisberg, 1991) using stages from the Global
Deterioration Scale (Reisberg et al., 1982) (Panza et al., 2005). Six stages comprise the
Global Deterioration Scale: Stage 1 (no cognitive decline), Stage 2 (very mild cognitive
decline), Stage 3 (mild cognitive decline), Stage 4 (moderate cognitive decline), Stage 5
(moderately severe cognitive decline), and Stage 6 (severe cognitive decline). Although
the Global Deterioration Scale was designed to assess degenerative dementia and
describe its stages, it was noted by the group from New York University that a number of
patients fell into stages 2 and 3 and that these patients were exhibiting mild cognitive
impairment instead of dementia.
Diagnostic Criteria and Impairment Cutoffs: Contributions of the Max Planck I
nstitute
As previously noted, diagnostic criteria were not proposed when the term MCI
was conceptualized because the label of MCI was only applied to patients scoring in a
designated range on a single measure (i.e., the Global Deterioration Scale). In 1992,
Zaudig attempted to reclassify MCI according to existing diagnostic systems. After
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administering the Structured Interview for the Diagnosis of Dementia of the Alzheimer
Type, multi-infarct dementia, and dementias of other etiology (SIDAM: Zaudig et al.,
1991; Zaudig & Hiller, 1991) to a sample of 150 randomly selected older adults living in
Germany, patients with cognition anddaily functioning consistent with dementia and MCI
were identified.
Using the Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition
Revised (American Psychiatric Association, Diagnostic and Statistical Manual of Mental
Disorders, 3rd ed., revised [DSM-III R], 1987) criteria, two types of MCI patients were
classified. Type 1 patients (MCI Type 1) exhibited characteristics identical to the DSMIII-R diagnostic criteria for Amnestic Syndrome: memory impairment (short- and longterm memory) but no impairments in any other cognitive domain. The other type (MCI
Type 2) exhibited impairments to memory and another cognitive domain.
Using International Statistical Classification of Disorders (World Health
Organization, International Statistical Classification of Disorders and Health Related
Problems, 10th Revision [ICD-10], 1992) criteria, three “types” of MCI patients were
classified. Type 1 and Type 2 patients were identical to those outlined by DSM-III-R
criteria. Type 3 patients (MCI Type 3), however, could display characteristics of either
MCI Type 1 or MCI Type 2 along with accompanying deterioration in emotional control,
social behavior, or motivation. Using these definitions in combination with performance
on the SIDAM, optimal scores for characterizing patients as normal, MCI Type 1, MCI
Type 2, MCI Type 3, and demented were reported. As can be seen, this work represented
a critical step forward in advancing a statistical approach to diagnosing MCI. However,
as will be detailed below, subsequent work did not capitalize on this.
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MCI Diagnostic/Research Criteria: The Contributions of Ronald Petersen
In what has become known as the “Petersen criteria” or “Mayo criteria” (Petersen
et al., 1997; Petersen et al., 1999) the first diagnostic/research criteria for MCI were
developed: (1) memory complaint, (2) normal daily functioning, (3) normal general
cognitive function, (4) abnormal memory for age, and (5) not demented (see Table 1).
Although this represented an important advance in the development of the MCI construct,
a number of limitations were present. First, memory impairment was deemed necessary,
but many older adults with impaired cognition do not have a primary impairment in
memory. Instead, many have primary impairment in other areas of cognition (e.g.,
executive dysfunction). Furthermore, evidence exists that in some patients, changes to
executive function precedes the onset of changes in memory (Carlson et al., 2009).
Second, clinical judgment is required on the part of the patient due to a subjective
memory complaint being a necessary criterion. This means memory impairment need not
only be present but also judged as present and reported by the patient. Third, “normal”
daily functioning must be exhibited, but what constitutes “normal” remains a judgment of
the clinician. Moreover, some declines in daily functioning are common in nondemented older adults, and this further complicates the reliance on clinical judgment.
Finally, phrases such as “normal general cognitive function” and “abnormal memory for
age” do not specify what constitutes normal from abnormal and, once again, lead to an
overreliance on clinical judgment. Is 1.0 standard deviation (SD) below the mean
abnormal? Is 1.5 SD below the mean abnormal? Should age and education be taken into
account? Answers to these questions are not clear from the criteria and, therefore,
clinicians must use their best judgment to decide.
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First Key Symposium
At the First Key Symposium in Stockholm, Sweden, in 2003, it was
acknowledged that MCI could have multiple etiologies and subtypes that are not mutually
exclusive and not necessarily related to a degenerative neurological disorder such as AD
(Winblad et al., 2004) (see Table 2). Another recommendation from this consensus
conference had to do with the second Petersen criteria (normal daily functioning). As a
result, patients with early and subtle changes to daily functioning could still be
considered for an MCI diagnosis. Moreover, a concrete definition of “subtle” was not
explicitly stated and a description about how to go about assessing these subtle changes
to daily functioning was not given. Consequently, the best way to assess for declines to
daily functioning and the threshold for “subtle changes” remained highly influenced by
clinical judgment.
Latest Recommendations for Research/Diagnostic Criteria
The most current recommendations for diagnostic/research criteria for MCI come
from a workshop organized by the National Institute on Aging and Alzheimer’s
Association (NIA/AA) (Albert et al., 2011). These criteria are very similar to original
Petersen criteria, and many of the issues regarding standardization and overreliance on
clinical judgment found in the original Petersen criteria remain unchanged (see Table 3).
Impairment in MCI: Overreliance on Clinical Judgment
In the most recent recommendations given for MCI diagnostic criteria (Albert et
al., 2011), impairment can be present in one or more cognitive domains (Table 3). The
following description of impairment was given by the NIA/AA workgroup: “There
should be evidence of lower performance that is greater than would be expected for the
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patient’s age and educational background. If repeated assessments are available, then a
decline in performance should be evident over time” (Albert et al., 2011, p. 271). A
critique of this definition has to do with how much clinical judgment is needed to
interpret the description. Specifically, what constitutes “lower performance?” Since it is
not explicitly stated, this question is left to the judgment of the clinician. Moreover,
reference is given to a “decline in performance over time” but no specifications as to
what constitutes decline. Does this mean one, five, or ten percentage points in relation to
age- and education-matched peers? Once again, this determination is left to the judgment
of the clinician.
Later in the Albert et al (2011) paper, it is noted: “Cognitive testing is optimal for
objectively assessing the degree of cognitive impairment for an individual. Scores on
cognitive tests for individuals with MCI are typically 1 to 1.5 SD below the mean for
their age- and education-matched peers on culturally appropriate normative data (i.e., for
the impaired domain(s), when available). It is emphasized that these ranges are
guidelines and not cutoff scores” (Albert et al., 2011, p. 273). It is interesting that this
recommendation is not included with the actual diagnostic criteria and that the
impairment ranges are considered “guidelines and not cutoff scores.” By setting clear
impairment cutoffs, the diagnosis of MCI can be more standardized and, therefore, less
reliant on clinical judgment. Moreover, the difference between a standard deviation of 1
SD and 1.5 SD below the mean is a relatively wide range. In terms of percentiles, this
places the range between the 7th and 16th percentile, meaning the patient would have to
score worse than either 84% or 93% of the population after correcting for age and
education. Consequently, even for clinicians choosing to use less clinical judgment by
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following the guidelines, judgments must be employed in order to choose which cutoffs
to use.
Another problem with this description of impairment is the failure to take into
account premorbid intelligence. Simply stated, premorbid intelligence is an estimate of a
person’s cognitive functioning before changes in cognition started to appear. This need
to evaluate current cognition in relation to pre-morbid intelligence is highlighted by the
Guidelines for the Evaluation of Dementia and Age-Related Cognitive Decline
(American Psychological Association, 2011). Although these guidelines are described as
aspirational and not enforceable, guideline 4 states that psychologists should attempt to
estimate premorbid intelligence when measuring cognitive changes in individuals.
Without an estimate of premorbid intelligence, determining a change in cognition is
difficult and left to the judgment of the clinician. For instance, an older adult with an
estimated pre-morbid Intelligence Quotient (IQ) falling into the 16th percentile would be
demonstrating no decline in relation to peers using a 1.0 SD cutoff. However, the same
older adult would be considered impaired using the recommendations from Albert et al.
(2011). In contrast, interpretation would be quite different for an older adult with an
estimated premorbid IQ falling at the 84th percentile. For this patient, performance on
cognitive measures falling at the 50th percentile represents a fairly substantial decline in
cognition, and performance falling into the 16th percentile represents a change in
cognition of two SD. Without taking into account pre-morbid intelligence, the same
impairment threshold would be used when, in reality, the first patient is exhibiting no
changes in cognition while the second patient is exhibiting drastic changes in cognition.
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Ideally, obtaining an estimate of premorbid IQ would be as easy as reading a
WAIS report that was administered to the patient sometime in the past, but these kinds of
records are rarely available. Instead, a neuropsychologist should evaluate a skill that is
relatively resistant to the changes in cognition associated with MCI and dementia. This is
most easily accomplished by evaluating reading ability because reading ability does not
significantly differ in relation to peers even in older adults diagnosed with mild dementia
(McGurn et al., 2004). However, minor changes in reading have been noted early in the
course of dementia, and these changes increase as the disease progresses (Cockburn et al.,
2000; O’Carroll et al., 1995; Patterson, Graham, & Hodges, 1994). Consequently, for
patients with moderate to severe dementia, reading ability cannot be relied upon to yield
an accurate estimate of pre-morbid intelligence.
Measures such as the American National Adult Reading Test ANART (Nelson &
O’Connell, 1978) provide a good example of how to best assess reading to gain an
estimate of pre-morbid intelligence. The ANART contains 50 low-frequency/irregular
English words (e.g., ache and thyme), and the patient is instructed to read aloud each
word with the number of words correctly pronounced comprising a total score.
Normative data correcting for age, gender, and education are available (Kiely et al.,
2011). Other techniques such as using a statistical model designed to estimate premorbid
intelligence from demographic variables are available (Crawford, Millar, & Milne, 2001).
Although reading tests such as the ANART have been shown to yield the most accurate
estimates of premorbid IQ, measures combining reading ability, best performance, and
demographic variables are needed and have the potential to be more accurate than a test
of reading ability used in isolation (Griffin et al., 2002).
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Turning again to the example case, it can clearly be demonstrated how clinical
judgment must be used given the ambiguous nature of the current MCI diagnostic
criteria. Even following the recommendations given by the Alzheimer’s workgroup (1
SD to 1.5 SD below the mean), clinical judgment is still needed in determining a
diagnosis. Mary exhibited general cognitive functioning falling at the 25th percentile and
immediate memory falling at the 20th percentile. No clinical judgment is needed because
these scores are above both recommended cutoffs. However, she exhibited delayed
memory falling at the 15th percentile, and this score falls into the gray area between 1 SD
and 1.5 SD below the mean. Does this mean that impairment is present and a diagnosis
of amnestic MCI applicable? Unfortunately, clinical judgment will be needed to decide.
It is also difficult to ascertain the significance of Mary’s scores because an estimate of
premorbid intelligence was not obtained. Is Mary’s premorbid intelligence average,
below average, or above average? This information would certainly give a better
perspective about her current scores, but this information is not available.
NIA/AA Recommendations and Biomarkers and Imaging
Criteria from the Alzheimer’s Workshop are divided into two parts: one
containing reference to biomarkers and imaging and one not containing reference to
biomarkers and imaging. Biomarkers and imaging under examination and MCI criteria
incorporating biomarkers and imaging are listed in Tables 4 and 5, respectively. Taken
together, these criteria offer an exciting advancement in the diagnosis of MCI. However,
the inclusion of biomarkers and imaging is still considered an exploratory step. As noted
by Albert and colleagues, this inclusion is to “determine the likelihood of cognitive and
functional progression for an individual MCI patient to a more severe stage of MCI or to
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dementia, and the likelihood that this progression will occur within a defined period” (pg.
275). Albert and colleagues go on to note that imaging and biomarkers are not validated
in MCI and that studies are largely confined to the examination of patients with AD. For
studies examining MCI patients, few have compared biomarkers and imaging with each
other or with histopathologic confirmation. Furthermore, studies combining multiple
biomarkers and imaging data have not been conducted. Taken together, this means that
predictive studies regarding imaging and biomarkers in relation to MCI are greatly
needed to advance diagnostic accuracy. (A brief review of imaging and biomarkers in
AD can be found later in this proposal).
MCI: Estimates of Prevalence and Incidence are Inconsistent
Earlier it was stated that one effect of clinical judgment could be that the samples
used in MCI research may, in fact, be representative of quite different populations. This
critique is well supported by research on the prevalence and incidence of MCI in the
general population. From 1995-2009, nine studies on MCI incidence rates were
conducted in North America, South America, and Europe. Although each of these nine
studies used similar diagnostic criteria, application of these criteria varied from study to
study. As noted in a review by Luck et al. (2010), MCI diagnostic criteria were modified
in four of the nine studies. In three studies, a subjective report of cognitive impairment
was not required, and in one study a subjective report of cognitive impairment and
preserved daily functioning were not required (the daily functioning criteria used in this
study is similar to the most recent diagnostic recommendations made by the Alzheimer’s
workgroup.). Impairment thresholds also varied among studies. Performance less than
1.5 SD below the mean, less than 1.0 SD below the mean, and less than the 10th
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percentile in relation to age-, education-, and sometimes gender- and race-corrected
scores were all used (Luck et al., 2010).
Given the wide array of differing applications of the MCI diagnostic criteria in
incidence studies (both for Petersen and MCI-R criteria), it is not surprising the range of
estimates of MCI incidence is quite large. For any MCI type, estimates range from 8.576.8 per 1,000 person-year (Ravaglia et al., 2008; Solfrizzi et al, 2004; Tervo et al., 2004;
Chaves et al., 2009; Caracciolo et al., 2008; Manly et al., 2008; Verghese et al., 2006;
Busse et al., 2003; Larrieu et al., 2009; Lopez et al., 2003). Estimates for amnestic MCI
range from 8.5-40.6 per 1,000 person-year while estimates of non-amnestic MCI range
from 28-36.3 per 1,000 person-year. Higher estimates were noted in studies that did not
require a subjective report of cognitive impairment. As can be seen from these estimates,
the incidence of MCI in the population is not well understood and reflects a need for the
standardization of the diagnostic criteria. Age, education, and vascular risk factors were
consistently associated with increased incidence of MCI. No studies on the incidence of
MCI using criteria proposed by the Alzheimer’s workgroup have yet been conducted.
Several studies have been conducted comparing the prevalence of MCI in the
population according to both MCI and MCI-R criteria. As with the incidence studies
discussed above, the interpretation of the criteria vary from study to study and also
highlight the need for standardized criteria. For instance, in a sample of 3,327 older
adults over the age of 75 who were receiving care from a general practitioner, the
prevalence of MCI was 15.4% using Petersen criteria and 25.2% using MCI-R criteria
(Luck et al., 2007). The SIDAM was used to evaluate cognitive impairment, and domain
specific cognitive impairment was considered present if performance fell more than 1 SD
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below the mean using age- and education-corrected scores. The SIDAM-ADL scale was
used to evaluate daily functionin, and patients with one or no impairments on the 14
SIDAM-ADL items were considered functionally unimpaired. Significant risk factors
included age, vascular disease, depression, and APOE4 genotype.
In a study of 883 older adults over the age of 60 receiving care from a general
practitioner, the prevalence of MCI was 16.6% using MCI-R criteria but fell to 3% when
using Petersen criteria (Artero et al., 2006). A computerized neuropsychological
evaluation assessing a number of cognitive domains was used to evaluate for cognitive
impairment. Patients were considered impaired if performance fell more than 1.5 SD
below age- and education-corrected scores on a memory or other cognitive task. Daily
functioning was required to be “essentially normal” (Artero et al., 2006, p. 467).
However, specifics about the evaluation of daily functioning were limited to the
following quote: “A validated activity of daily living scale with finely graded hierarchical
subscales was used to assess alterations in everyday functioning in collaboration with
both subjects and caregivers” (Artero et al., 2006, p. 466).
The two studies outlined above were chosen to highlight how lack of standardized
criteria can lead to differing estimates using Petersen and MCI-R criteria in a similar
sample (i.e., patients of general practitioners). In the study by Luck et al (2007), the
authors judged impairment to be present if scores fell more than 1 SD below the mean
using age- and education-corrected scores on a neuropsychological test. However, in the
Artero and colleagues’ study, the authors did not judge impairment to be present until
age- and education-corrected scores were more than 1.5 SD below the mean. Evaluation
of daily functioning was also not uniform between the two studies. In Luck and
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colleagues’ study, a patient’s daily functioning was judged as impaired if difficulties in
two or more areas were displayed. However, daily functioning was required to be
essentially normal by Artero and colleagues. Although comparisons between the
prevalence estimates noted in these two studies are not appropriate due to the difference
in ages of the samples (75+ vs. 60+), it can easily be seen how clinical judgment would
lead to different prevalence estimates even when using an identical sample. No studies
on the prevalence of MCI using criteria proposed by the Alzheimer’s workgroup have yet
been conducted.
Conversion from MCI to Dementia: Varying Estimates
As with estimates of incidence and prevalence, the role of clinical judgment in the
interpretation of MCI diagnostic criteria has contributed to uncertainty regarding
prognosis. For some patients diagnosed using current criteria, an improvement in
cognition can be expected. For others, cognition will remain stable. For still others,
cognition will continue to decline until a diagnosis of dementia is warranted. However,
these estimates vary widely in the research literature. A review of studies of dementia
conversion well illustrates this point.
In a study using original Petersen criteria, 32.2% of patients diagnosed with MCI
progressed to dementia within two years (Amieva et al., 2004). In this study, general
cognitive functioning was judged to be intact for patients with at least a primary school
education and scoring >25 on the MMSE. For patients with less education, general
cognitive functioning was judged as intact if scores were >23 on the MMSE. For both
education groups, domain specific impairment was judged as present if scores were more
than 1.5 SD below the mean using age- and education-corrected scores on either a test of
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working memory or semantic fluency. No dependency for basic ADLs and slight
dependency for higher-order ADLs were required for an MCI diagnosis. In another study
in which a differing interpretation of original Petersen criteria was used (i.e., MMSE
scores <25 regardless of education for intact general cognitive functioning, 1.0 SD cutoff
for domain specific impairment, and normal daily functioning), a conversion rate of 27%
was noted over the course of ten years, and only 15% of patients progressed to dementia
over the first two years (Ganguli et al., 2004).
MCI-R criteria have been noted as exhibiting better predictive validity of
conversion to dementia (sensitivity of 95% and specificity of 66%) than the original
Peterson criteria (sensitivity of 5% and specificity of 91%) when the same impairment
cutoffs are used for both groups (Artero et al., 2006). However, issues are also present
with MCI-R criteria as the application of these criteria can lead to strikingly different
conversion estimates. For instance, when using cutoffs of more than 1 SD and more than
1.5 SD below the mean on the SIDAM for both Petersen and MCI-R criteria, the best
predictive validity (sensitivity of 74% and specificity of 73%) was observed when MCI-R
criteria was coupled with a 1 SD cutoff (Busse et al., 2006). When using a 1.5 SD cutoff,
specificity increased to 86.1% but at the expense of a decrease in sensitivity to 40.4%.
Overall, conversion rates varied by 45% depending on which diagnostic criteria were
used and how they were applied. No studies of rates of conversion from MCI to
dementia using criteria proposed by the Alzheimer’s workgroup have yet been conducted.
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Proposing an Statistical Model: A Two-Step Process
The Two Steps
As outlined in Tables 2 and 3, the etiology of MCI (i.e., degenerative, vascular,
metabolic, traumatic, psychiatric, and other) can vary from patient to patient. These
etiologies also have significant long-term implications. For example, if the cause of MCI
is a degenerative brain disorder (i.e., AD or other types of dementia), then MCI is
considered a predementia syndrome and will continue to progress until the death of the
patient; however, if the cause is reversible (i.e., metabolic and psychiatric), treatments
can be applied to help the patient’s cognition remain stable or improve. As a concept,
MCI is designed to identify patients in the first category: those who will eventually go on
to develop a dementia syndrome. But in practice, patients in both groups are diagnosed
with MCI. This means patients with cognitive decline stemming from depression,
anemia, thyroid disease, and/or a vitamin deficiency will be diagnosed the same as
patients in the preclinical stages of a dementia syndrome.
Using a statistical model, MCI patients could be classified based upon risk for
conversion. Essentially, this would divide MCI into two groups based upon risk
determined by comparison to a single cut-score. For one group, risk for conversion would
be high. For the other group, risk for conversion would be low. Furthermore, through the
application of screening and conversion models (explained below), issues present in
current research studies could be mitigated to a large degree. To construct such a model,
two steps are needed. Step 1 would involve constructing a “screening” model, and Step 2
would involve constructing a model to predict conversion.
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Step I: Screening Patients for Application of a Conversion Model
A screening model used to identify patients to be evaluated by a conversion
model should be weighted in favor of including false-positives over false-negatives. This
is because a screening model is aimed at determining which individuals need a more
thorough and expensive evaluation so the conversion model can be applied. However,
for the purpose of ease and consistency among samples used in research studies, the
importance of using standardized criteria with the least amount of reliance on clinical
judgment cannot be overstated (see Table 6 for recommendations).
First, it is recommended that patient judgment (subjective complaints), family
judgment (family reports of decline), informant judgment (reports from non-family
members that decline is present), and clinical judgment (reports from providers) be
excluded from a screening model. Second, objective evidence of impairment should be
standardized and pre-morbid IQ taken into account. As recommended by Busse et al.
(2006), a cutoff of 1.0 SD below the mean should be used to best optimize the number of
older adults identified as at risk for conversion to a dementia syndrome. Although this
cutoff inflates the number of false-positives to a degree, it reduces the risk of not
identifying patients who will later go on to develop dementia. Given the opportunity to
treat and study these predementia patients, the increased rate of false-positives seems an
acceptable compromise. Moreover, application of the second model (i.e., conversion
model) would further mitigate the increased rate of false-positive results. In other words,
those who were falsely identified as MCI by the simple screening model could later be
correctly identified using the more complex conversion model. Third, an older adult
should not be considered impaired if scores do not fall more than 1.0 SD below estimates
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of pre-morbid IQ. As outlined earlier in this proposal, older adults who exhibited
cognitive abilities at the 10th percentile when they were 20 years old should not be
considered impaired if performance falls at the 10th percentile when they are 70 years old.
Fourth, functional abilities and daily functioning should be evaluated with a functional
measure validated on the patient population being assessed. Moreover, essentially
normal daily functioning should not be required because older adults can experience
some changes in functional abilities not related to cognitive impairment and, therefore,
not indicative of dementia (similar to MCI-R criteria). With these recommendations,
clinical judgment can be taken out of a screening model. Furthermore, the simplicity of
the proposed screening model would work to lessen the constraints of human cognitive
limitations.
The screening model based on the above recommendations would have four
components: (1) scores >1 SD below mean age- and education-corrected scores on a test
of general cognitive functioning (i.e., ADAS-COG); (2) scores ≤1 SD below mean ageand education-corrected scores on a measure evaluating a specific cognitive domain (i.e.,
memory); (3) performance on domain specific test is ≤1.5 SD below estimate of
premorbid intelligence; and (4) no difficulty or mild difficulty in any daily functioning
domain as determined by scores on an empirically validated functional measure.
By using Mary’s scores corrected for age and education as an example, it can be
demonstrated how this screening model could be used for amnestic MCI. On a test of
general cognitive functioning, Mary scored in the 25th percentile. This score indicates
that her general cognitive functioning is not considered impaired so a + is noted for the
first part of the model. On tests of memory, she scored in the 20th percentile for Total
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Recall and in the 15th percentile for Delayed Recall. Her score on Delayed Recall is ≥1
SD below the mean so a + is also noted for the second part of the model (domain specific
impairment). Although not administered an empirically validated functional measure,
Mary’s daily functioning was reported as normal so a + is noted for the fourth part of the
model. However, by relying on family reports, family judgment has been used to
determine if a + was warranted for the parts of the equation related to ADL and IADL
functioning. This emphasizes the importance of using an empirically validated functional
measure as part of a neuropsychological assessment so clinical judgment can be taken out
of the equation.
So far, Mary has received a + on all addressed parts of the model. However,
Mary’s premorbid intelligence was not assessed. Because of this oversight, the screening
model cannot be completed. If, for example, Mary’s performance on the ADAS-COG
(25th percentile) is reflective of her premorbid intelligence, she would receive a – for the
third part of the equation because her Logical Memory score is within 1 SD. In contrast,
a + would be warranted if her performance on the ADAS-COG is not reflective of her
premorbid intelligence. For example, if Mary’s premorbid intelligence fell at the 67th
percentile, her score on Delayed Recall would be more than 1 SD lower. Consequently, a
+ would be noted for the third part of the model. However, the screening model is only a
step to identify people most in need for evaluation from the second (conversion) model.
If any question arises about a patient, the steps needed to apply the second model should
be taken. For example, the screening model was not able to be fully completed for Mary
because her premorbid intelligence was not evaluated. However, a discrepancy was
noted between scores on tests of general cognitive functioning and memory.
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Consequently, it is recommended that Mary take the steps needed for the conversion
model to be applied.
Step II: Constructing a Model to Predict Conversion to Dementia
Statistical models for predicting dementia risk in the older adult population can be
found in the literature. The models with the best predictive validity are multifactorial and
use data from neuropsychological testing, patient and informant report, imaging, genetics,
and other demographic and health information. The most complex of these models is the
Late-Life Dementia Risk Index (Barnes et al., 2009). This index uses age, cognition
(scores on two short screens), body mass index, ApoE4, imaging, vascular risk factors,
functional abilities, and factors related to lifestyle to generate placement in three groups:
low-risk (index score of 0-3), moderate-risk (index score of 4-7), and high-risk (index
score ≥8).

Although models such as the Late-Life Dementia Risk Index exist, their

utility is limited because in clinical practice it is extremely rare to have access to
information about so many risk factors, and many steps would be needed to gain
information for the average patient. This demonstrates two needs: (1) models need to be
designed that target MCI patients instead of the general population, and (2) standardized
criteria need to be developed that identify at risk patients so a conversion model can be
applied. However, to date no multifactorial conversion models of this type have been
developed.
As can be seen from the Late-Life Dementia Risk Index, biomarker and imaging
data are important parts of a comprehensive model designed to predict dementia risk.
However, as noted earlier, research regarding biomarkers and imaging in relation to MCI
is in its infancy. For the current study the following biomarkers and types of imaging are
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candidates for inclusion in a statistical model designed to predict conversion from MCI to
AD: (1) Homocysteine is a non-protein amino acid and associated with AD in studies
comparing autopsied patients with AD versus controls (reviewed in Frank et al., 2003).
Increased homocysteine levels are associated with a four times greater risk for AD; (2)
Oxidative/nitrative damage is associated with AD, and specific isoprostanes are elevated
in the urine, blood, and CSF of AD patients. Moreover, oxidative/nitrative damage is
correlated with memory impairments, CSF tau levels, and the number of APOE4 alleles
(Frank et al., 2003; Pratico et al., 2000; Pratico, Clark, Liun, Lee, & Trojanowski, 2002;
Pratico, Uryu, Leight, Trojanoswki, & Lee, 2001; Pratico, V, Trojanowski, Rokach, &
Fitzgerald, 1998; Reckess, 2003; Yao et al., 2003); (3) Recent studies have shown that
sulfatide (a major constituent of brain lipids) may be associated with AD (reviewed in
Reckess, 2003). Sulfatide decreases up to 93% in gray matter and 58% in white matter in
MCI versus controls. Furthermore, CSF sulfatide may differentiate non-demented
individuals from those with very mild dementia; (4) Tau and Aβ (components of tangles
and plaques, respectively) are the most commonly studied potential AD biomarkers. CSF
tau levels are associated with AD pathology (decreased in patients with AD), and CSF
tau levels aid in the differential diagnosis of AD from other dementing disorders (Arai et
al., 1998; Arai, Morikawa et al., 1997; Arai et al., 1995; Araiet al., 1997; Clark et al.,
2003; Frank et al., 2003; Reckess, 2003); (5) Using MRI images, it has been shown that
neurodegeneration of the medial temporal region and specifically the left hippocampus
can be used to predict conversion from MCI to dementia (Risacher et al., 2009); (6)
Abnormal patterns of glucose use have been associated with AD. Using PET images, it
has been shown that reduced glucose in the limbic structures and in particular the
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hippocampus is associated with MCI and subsequent conversion to dementia (reviewed
in Schuff & Zhu, 2007).
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RESEARCH QUESTIONS AND HYPOTHESES

The current study will address the following research questions:
1.

Can demographic factors be used to predict conversion from MCI to

dementia? It is hypothesized the female gender and low education will yield the
highest predictive values.
2.

Can neuropsychological testing be used to predict conversion from MCI to

dementia? It is hypothesized Logical Memory – II will yield the highest predictive
value of any measure.
3.

Can biomarkers collected from CSF, urine, or blood be used to predict

conversion from MCI to dementia? It is hypothesized homocysteine levels will
yield the highest predictive value.
4.

Can brain imaging be used to predict conversion from MCI to dementia? It

is hypothesized hypometabolism in the hippocampal brain area will yield the
highest predictive value.
5.

Can daily functioning be used to predict conversion from MCI to

dementia? It is hypothesized performance on tests of neuropsychological
functioning will be a better predictor of conversion than daily functioning.
6.

Can neuropsychiatric functioning be used to predict conversion from MCI

to dementia? It is hypothesized depression will yield the highest predictive value
of any behavioral abnormalities.
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7.

Can data from neuropsychological testing, demographic variables,

biomarkers, brain imaging, daily functioning, and neuropsychiatric functioning
be used to construct a statistical model that predicts conversion from MCI to
dementia with a high level of accuracy? Furthermore, can this model be used to
predict conversion from MCI to dementia better than predictions made from any
single variable or variables from any factor groups (i.e., neuropsychological
testing, demographic variables, biomarkers, and brain imaging)?
8.

What diagnostic criteria can be used to construct an optimal screening

model? For example, does a 1.0 SD or 1.5 SD cutoff using age- and educationadjusted scores on tests of neuropsychological functioning yield more acceptable
inclusion rates in application of the screening model? Also, does using premorbid
intelligence increase the psychometric properties of a screening model? Finally,
does allowing for some minor difficulties with ADLs yield a more optimal
screening model? It is hypothesized that using a 1.0 SD cutoff will be preferable
to using a 1.5 SD cutoff, that taking premorbid intelligence into account will
increase the psychometric properties of the screening model, and that allowing for
some minor trouble with ADLs will further increase the psychometric properties
of a screening model.
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METHODS AND MATERIALS

Subjects
Data for the current study came from the publicly available portions of the
Alzheimer’s disease Neuroimaging Initiative (ADNI). The ADNI is a non-randomized,
natural history non-treatment study of biological and neurocognitive factors in MCI. In
total, 800 subjects (200 normal controls, 400 MCI, and 200 mild AD) were recruited
from 50 sites in the United States and Canada. Subjects were between the ages of 55-90
at the time of inclusion and required to provide an informant who could answer questions
about the subject’s general functioning. All subjects were required to consent to all test
procedures and agree to longitudinal follow-up. No subjects were included who were
currently taking psychoactive medications. The conversion from normal to MCI or AD
and conversion from MCI to AD is of considerable interest. ADNI researchers estimate
the most frequent conversion will be from MCI to AD and will occur at approximately
10-15% per annum.
For ADNI criteria, normal controls were required to score between 24-30 on the
MMSE, have a Clinical Dementia Rating (CDR) score of 0, and be non-depressed. MCI
subjects were required to score between 24-30 on the MMSE, have a history of a memory
complaint (from the subject or informant), fall below education-adjusted cutoff scores on
the Logical Memory II subscale from the Wechsler Memory Scale – Revised (≤8 for 16
or more years of education, ≤4 for 8-15 years of education, and ≤2 for 0-7 years of
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education), have a CDR of 0.5, have no impairment in domains other than memory and
essentially normal ADLs. Mild AD subjects were required to have a history of a
memory complaint (from subject or study partner) and abnormal memory function as
indicated by education adjusted cutoffs on the Logical Memory II subscale from the
Wechsler Memory Scale – Revised (same cutoffs used for MCI), MMSE between 20 and
26, CDR of 0.5 or 1.0. They also had to meet National Institute of Neurological and
Communicative Diseases and Stroke/Alzheimer’s Disease and Related Disorders
Association (NINCDS/ADRDA) criteria for probable AD (McKhann et al., 1984). These
criteria are as follows: memory impairment established by neuropsychological testing
(using the standardized test battery), deficits (≤5th percentile using age- and educationcorrected scores) in two or more areas of cognition, evidence of continued decline from a
previous level of functioning through a collateral source and structured clinical
examination or assessment of activities of daily living, no disturbance of consciousness,
onset between ages 40 and 90, and the absence of systemic disorders or other brain
diseases that could account for the progressive deficits in memory and cognition. These
criteria have been shown to achieve good reliability and validity in the diagnosis of AD
when compared with autopsy confirmed cases (Blacker et al., 1994).
To retain a high level of consistency between diagnostic categories, attempts were
made to use ADNI criteria whenever possible. Consequently, the same cutoffs on the
MMSE and CDR were used across diagnostic category. Four distinct samples were
utilized for this study: patients identified as MCI using ADNI criteria, patients identified
as MCI according to a 1.0 SD cutoff on Logical Memory Delayed and <6 on the FAQ
(proposed criteria #1), patients identified as MCI according to a 1.5 SD cutoff on Logical
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Memory Delayed and <6 on the FAQ (proposed criteria #2), and patients identified as
MCI using a 1.5 SD cutoff in relation to VIQ and <6 on the FAQ (proposed criteria #3).
Criteria used for each diagnostic classification system can be found in Table 7.
Procedures
After baseline visits were complete, an experienced neurologist or psychiatrist
determined the best diagnosis (normal, MCI, AD, or other). The diagnosing
physician reviewed the medical history and all information gathered at the baseline visits
to determine if there was significant impairment or deterioration. Based on the results of
the clinical, neuropsychological, and laboratory information, the physician may have
made a diagnosis and, if appropriate, further classified the diagnosis of AD into Probable
AD or Possible AD. For the purposes of the ADNI database, Possible AD refers to
situations where a second disorder is present that may cause dementia but is not
considered to be the primary cause of the dementia (i.e. AD is considered to be the
primary cause). If the subject had developed another diagnosis other than AD which is
believed to be the primary etiology for cognitive impairment or dementia, this was also
be specified.
At baseline, subjects underwent clinical and cognitive assessments. Structural
magnetic resonance imaging (1.5T MRI) was conducted at designated intervals for the
length of study inclusion (2-3 years) for all subjects. Approximately 50% of subjects also
had Fluoro Deoxy Glucose Positron-Emission Tomography (FDG PET) scans at the same
designated intervals. An additional 25% of subjects were not scanned using PET had
MRI at 3 Tesla for greater image resolution. All subjects were evaluated at 0, 6, 12, and
24 month intervals. In addition, MCI subjects were evaluated at 18 and 36 months, and
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normal controls were evaluated at 36 months. IRB approval was obtained at all affiliated
sites, and signed consent was required from all subjects and informants before inclusion.
Further details about study procedures including pre-screening, data management, and
quality control can be found online at
http://www.adniinfo.org/Scientists/Pdfs/adni_protocol_9_19_08.pdf.
Demographic Variables of Interest
A number of studies have found education to protect people from developing
dementia (Brayne et al., 2010; Del Ser et al., 1999; Letenneur et al., 1999; Ott et al.,
1995; Stern et al., 1994; Valenzuela et al., 2008; Valenzuela and Sachdev, 2006). Results
of some studies indicate that females are more likely to develop dementia than males with
gender differences becoming more pronounced for people over the age of 85 (Anderson
et al., 1999; Brayne et al., 1995; Clark et al., 1996; Fratiglioni et al., 1997; Morgan et al.,
1993; Yoshitake et al., 1995).
Measure of Dementia Severity
Clinical Dementia Rating (CDR):
The CDR (Berg, 1988) describes five degrees of impairment in performance on
each of 6 categories: memory, orientation, judgment and problem solving, community
affairs, home and hobbies, and personal care. The ratings of degree of impairment
obtained on each of the 6 categories of function are combined into one global rating of
dementia (ranging from 0 to 3). The CDR has been shown to be reliable and valid for use
with both diagnosis and staging in AD patients (Morris, 1997).
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Measures of Neuropsychological Functioning
Mini-Mental State Examination (MMSE):
The MMSE (Folstein et al., 1975) is a brief screening measure of general
cognitive functioning and assesses the following cognitive domains: orientation,
registration, short-term recall, attention, calculation, visuo/constructional skills and
praxis. Total scores range from 0-30. Various cut-scores have been used to classify
levels of cognitive impairment with scores ≤ 24 typically being indicative of cognitive
impairment (Tombaugh & McIntyre, 1992). Normative data correcting for age and
education is also available (Crum et al., 1993). Although demonstrating utility as a short
screening measure for cognition (Clark et al., 1999), the MMSE is not an accurate standalone measure for the diagnosis of AD (Tierney et al., 2000)
Alzheimer’s Disease Assessment Scale-Cognitive (ADAS-COG):
The ADAS-COG (Rosen, Mohs, & Davis, 1984) is a structured measure that
evaluates the following domains: memory (word recall and word recognition), reasoning
(following commands), language (naming and comprehension), orientation, ideational
praxis (placing a letter into an envelope) and constructional praxis (copying geometric
designs). Ratings of spoken language, language comprehension, word finding difficulty,
and ability to remember test instructions are also obtained. The number of errors made
determines overall test score (0-70). Higher scores indicate greater impairment.
Logical Memory Test (Delayed Paragraph Recall):
The Logical Memory test that was administered is a modification of the episodic
memory measure from the Wechsler Memory Scale-Revised (WMS-R) (D Wechsler,
1987). Free recall of one short story (Story A) consisting of 25 bits of information was
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recalled by the subject immediately after verbal presentation. A delay condition of 30
minutes is also included. The total bits of information from the story that are recalled
immediately (maximum score = 25) and after the delay interval (maximum score = 25)
are recorded. A retention or “savings”
score can be computed by dividing the score achieved during delayed recall by the score
achieved during immediate recall.
Boston Naming Test (BNT):
The BNT (Kaplan, Goodglass, & Weintraub, 1983) is a measure of visual
confrontational naming. Subjects are required to name objects depicted in line drawings.
For the ADNI, only 30 items were presented (either the odd- or even numbered items
from the full 60-item test). The drawings are graded in difficulty with the easiest
drawings presented first. If a subject encounters difficulty in naming an object, a
stimulus/semantic cue (e.g., it is found in Egypt) and/or a phonemic cue (saying the first
phonemes of the word) is provided. The number of spontaneous correct responses
(maximum score = 30) and spontaneous plus semantically-cued correct responses
(maximum score = 30) are recorded.
Category Fluency:
Category Fluency (Butters, Granholm, Salmon, Grant, & Wolfe, 1987) is a test of
verbal fluency. Subjects are instructed to generate as many examples as possible from
each of two semantic categories (animals and vegetables) in a 60-second time period.
Performance is measured by the number of correct, unique examples generated for the
two categories. Perseveration (repetitions of a correct item) and intrusion (non-category
items) errors are also noted.
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Clock Drawing Test:
The Clock Drawing Test (Goodglass & Kaplan, 1983) is a test of
visuoperceptual/construction skills and has two conditions: command and copy. In the
command condition, the subject is given a blank sheet of 8 1/2" X 11" paper and
instructed to “Draw a clock, put in all of the numbers, and set the hands for 10 after 11.”
After that task is completed, the subject is asked to copy a clock drawing. A quantitative
score (maximum total score = 10) is derived for each drawing by adding the scores of
three separate features: 2 points for the integrity of the clock face, 4 points for the
presence and sequencing of the numbers, and 4 points for the presence and placement of
the hands. The Clock Drawing Test is effective for discriminating between subjects with
AD and normal elderly individuals (Cahn et al., 1996).
Digit Span:
The Digit Span subtest from the WAIS-R (Wechsler, 1981) requires the subject to
recall a series of single digits that were orally presented. In the Forward condition, the
subject must repeat the digits in the same order. In the Backward condition, the digits
must be repeated in the reverse order. Testing is terminated when the subject misses both
trials at a given sequence length. A point is awarded for each correct sequence.
Maximum score range is between 0-14.
Rey Auditory Verbal Learning Test (AVLT):
The AVLT (Rey, 1964) is a test of learning and memory. Fifteen unrelated nouns
are verbally presented (one per second) across 5 learning trials. The number of correctly
recalled

35

words on each trial is recorded. Following a 20-minute delay, the subject is asked to
recall as many of the 15 words as possible. Directly following the delayed recall
condition, a yes/no recognition test is administered. The number of target “hits” and false
positive responses are recorded. Two equivalent alternate forms of the test were used
across test sessions so that subjects were exposed to the same word list as infrequently as
possible.
Trail Making Test:
The Trail Making Test (Reitan, 1958) consists of two parts: Part A and Part B.
For Part A the subject is instructed to connect 24 circles with a drawn line as quickly as
possible in ascending numerical order. For Part B, the subject is asked to connect the
circles while alternating between numbers and letters in an ascending order (e.g., A to 1;
1 to B; B to 2; 2 to C). The subject's performance is judged in terms of time (in seconds)
required to complete each trail and by the number of errors of commission and omission.
The time to complete Part A (150 second maximum) and B (300 second maximum) will
be the primary measures of interest. Although both Parts A and B depend on visuomotor
and perceptual-scanning skills, Part B also requires considerable cognitive flexibility in
shifting from number to letter sets under time pressure. Both parts of the Trail-Making
Test are available in multiple forms of equal difficulty for purposes of repeated
evaluation.
Digit Symbol Substitution:
Digit Symbol Substitution (Wechsler, 1981) is a subtest from the WAIS-R that
consists of 110 small blank squares (presented in seven rows), each randomly paired with
one of nine numbers (1 to 9) printed directly above it. Above the row of blank squares is
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a printed “key” that pairs each of the numbers 1 through 9 with an unfamiliar symbol.
Following a short series of practice trials, the subject must use the key to fill in the blank
squares in order (working left to right across the rows) with the symbol that is paired with
the number above it working as quickly as possible for 90 seconds. The number of blank
squares filled in correctly within the time limit is the measure of interest (maximum raw
score = 110). This test engages multiple cognitive abilities including attention,
psychomotor speed, complex scanning, visual tracking, and immediate memory.
Measure of Premorbid Intelligence
American National Adult Reading Test (ANART):
The ANART (Nelson & O’Connell, 1978) is a test of reading used as an estimate
of premorbid verbal intelligence. For the ANART, patients are required to read and
correctly pronounce 50 "irregular" words that do not follow common rules of
phonography and orthography. Consequently, correct pronunciation depends on previous
familiarity with the word. The 50 irregular words of the ANART are printed on a single
sheet of paper which is presented to the subject who is instructed to read each word
aloud. The number of mispronounced words is recorded by the examiner (maximum
errors = 50). Premorbid verbal intelligence can be estimated by applying a formula
derived by Grober and Sliwinski: (118.2 - .89 (AMNART errors) + .64 [years of
education]) (Grober & Sliwinski, 1991).
Biomarkers
Homocysteine is a non-protein amino acid implicated in AD.
Oxidative/nitrative damage is associated with AD and can be evaluated using the
blood, urine, and CSF of patients.
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Sulfatides are important components in muscle and nerve cell membranes and
have been implicated in AD.
Tau and Aβ are components of tangles and plaques, respectively and have been
highly implicated in AD.
Neuroimaging
MRI scans use a large magnet, radio waves, antenna, and computer to produce
clear images of the brain. By using MRI, invasive methods such as X-rays can be
bypassed. Using MRI images, it has been shown that neurodegeneration of the medial
temporal region and specifically the left hippocampus can be used to predict conversion
from MCI to dementia (Risacher et al., 2009).
PET images can be used to detect how the brain uses glucose. Abnormal patterns
of glucose use have been associated with AD.
Measure of Functional Impairment
Functional Activities Questionnaire (FAQ):
For the FAQ (Pfeffer, Kurosaki, Harrah, Chance, & Filos, 1982), a caregiver or
qualified partner is asked to rate the subject’s ability to carry out ten complex ADLs: (1)
manage finances, (2) complete forms, (3) shop, (4) perform games of skill or hobbies, (5)
prepare hot beverages, (6) prepare a balanced meal, (7) follow current events, (8) attend
to television programs, books or magazines, (9) remember appointments, and ((10) travel
out of the neighborhood. Each activity is rated as 0 (does without difficulty), 1 (needs
frequent advice or assistance), or 2 (someone has taken over the activity). Scores are
summed across items to provide a total disability score (higher scores = greater
impairment; maximum score = 20). If an activity was never or very rarely performed
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premorbidly, it is not rated and a pro-rated proportional score can be derived (achieved
score / [20 – 2 times the number of items rated as never performed]). Using the FAQ,
scores >5 have been shown to have predictive validity when distinguishing MCI from
mild AD (Teng et al., 2010).
Measures of Emotional and Behavioral Functioning
Neuropsychiatric Inventory Q (NPIQ):
The Neuropsychiatric Inventory (NPI) is used to assess both the frequency and
severity of behavioral abnormalities across 10 domains: delusions, hallucinations,
agitation, depression, anxiety, euphoria, apathy, disinhibition, irritability, and aberrant
motor behavior. Caregivers are asked to rate affected behaviors on a 1-4 scale for
frequency (1 occasionally, 2 often, 3 frequently, and 4 very frequently) and a 1-3 scale
for severity (1 mild, 2 moderate, 3 severe). Each domain is calculated by multiplying
frequency and severity. NPI Total score (range = 0-12) is the product of the 10 domains
designed to evaluate for behavioral abnormalities. The NPIQ (Kaufer et al., 2000) is a
shorter version that does only the screening questions and the severity rating for each
domain. The maximum score is 36.
Geriatric Depression Scale:
The Geriatric Depression Scale (Short Form) (Sheikh & Yesavage, 1986) is a
self-report measure of depression specifically designed for use with an older adult
population. The scale consists of 15 printed questions that the subject is asked to answer
by circling yes or no on the basis of how he/she felt over the past week. One point is
given for each positive or negative answer that is indicative of a symptom of depression,
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for a possible total of 15 points. Total scores of 0-5 are considered normal, and scores of
6-15 are considered evidence of clinically significant depression.
Statistical Analyses
Statistical analyses were conducted using SPSS version 20. For all models (see
Table 7), four steps were carried out. In the first step for all models, binary logistic
regressions were conducted for each set of variables: (1) demographic factors (APOE
included), (2) neurocognitive test scores, (3) biomarkers obtained from CSF, blood, and
urine, and (4) MRI and PET imaging. Factors meeting a more liberal significance
threshold of ≤0.1 for each class of variables were retained for the second step. For the
“hand selected” model, the second step consisted of factors being entered into a second
binary logistic regression and then removed until an unsatisfactory reduction in
Nagelkerke (or pseudo-R²) was noted. For all other models, the second step consisted of
remaining factors from each group being entered in a backward elimination binary
logistic regression. For the third step, scores for each patient were calculated using the
resulting regression equation (i.e., (constant) + (variable score*β)). Using the resulting
scores on the regression equation, receiving operating characteristic plots (ROC) were
calculated for each model. Using ROC plots, sensitivity and specificity for each subject
was obtained by taking sensitivity against 1-specificity (see Altman & Bland, 1994 for a
detailed description of ROC plots). For each model, the variable score is represented by
the patient’s performance on that variable (e.g., Logical Memory II score, hippocampus
volume, etc.). These scores are then multiplied by the unstandardized beta weight for
each variable obtained from conducting the regression. Next, these values and the
constant of the regression are summed into a single value that constitutes the predicted
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score. This score is then compared to the optimal cut-score that was obtained from the
ROC analysis of the distribution of all predicted scores. Next, the psychometric
properties corresponding to each equation (i.e., sensitivity, specificity, negative predictive
value, and positive predictive value) can be applied. Finally, a probability can be given
for the likelihood of converting to dementia.
A separate set of binary logistic regressions were also conducted to determine the
association between each resulting model to the diagnostic classification system from
which it was derived as well as the association across classification systems.
An independent sample t test was conducted to determine if daily functioning was
significantly different for converters versus nonconverters at baseline.
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RESULTS

Sample
Sample demographics for all patients identified as MCI according to all
classification systems can be found in Table 8.
Hypothesis #1: Can demographic factors be used to predict conversion from MCI to
dementia? It is hypothesized that the female gender and low education will yield the
highest predictive values.
No demographic variables were able to predict conversion from MCI to dementia
at the .01 level (gender, B=.245, p=.137; education, B=-.008, p=.765; race, B=.042,
p=.643; age, B<.001, p=.652) using ADNI diagnostic criteria.
Hypothesis #2: Can neuropsychological testing be used to predict conversion from
MCI to
dementia? It is hypothesized Logical Memory – II will yield the highest predictive
value of any measure.
Results of a backwards elimination regression using existing ADNI diagnostic
criteria demonstrated that neuropsychological testing can be used to predict conversion
from MCI to dementia with modest accuracy (pseudo R2 = .241, ROC = .823). Using the
optimal cutting score of -2.32, sensitivity of .80, and specificity of .71 was observed.
For lower equation scores, sensitivity increased at the cost of specificity. For higher
equation scores, specificity increased at the cost of sensitivity. Eleven variables were
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retained in the final equation based on neurocognitive performance, and four were
significant predictors at the .01 level (Table 9). As expected, Logical Memory – II
yielded the highest predictive value of any measure comprising the test battery (β=-.177,
p<.001).
Hypothesis #3: Can biomarkers collected from CSF, urine, or blood be used to
predict conversion from MCI to dementia? It is hypothesized that homocysteine levels
will yield the highest predictive value.
Results of a binary logistic regression show the only biomarker collected from
CSF, urine, or blood to be a significant predictor of conversion was level of amyloid-beta
(Abeta) 40 in plasma (β=-.017, p=.003) using ADNI diagnostic criteria. Homocysteine
was not a significant predictor of conversion (β=.014, p=.824). The following
biomarkers collected from CSF, urine or blood were also not significant predictors: 8-isoPGF2alpha isoprostane (β=.024, p=.814); 8,12-iso-iPF2alpha isoprostane (β=.054,
p=.102); alpha-synuclein (β=.138, p=.681); CSF Tau level (β=-.007, p=.322); Abeta1-42
(β=-.005, p=.322; pTau181p (β=.033, p=.192); and Abeta 42 (β=.036, p=.152).
Hypothesis #4: Can brain imaging be used to predict conversion from MCI to
dementia? It is hypothesized hypometabolism in the hippocampal brain area will
yield the highest
predictive value.
Results of a backwards elimination regression using existing ADNI diagnostic
criteria demonstrated that brain imaging can be used to predict conversion from MCI to
dementia with modest accuracy (pseudo R2=.371, ROC=.859). Using the optimal cutting
score of -2.04, predicted values generated by the equation achieved sensitivity of .85 and

43

specificity of .71. For lower equation scores, sensitivity increased at the cost of
specificity. For higher scores, specificity increased at the cost of sensitivity. Eleven
variables were retained in the final equation based on brain imaging and seven were
significant predictors at the .01 level (Table 10). Cumulative temporal lobe atrophy
yielded the highest predictive value of any imaging variable (β=-.063, p<.001).
Using ADNI criteria, the only PET variable that was a significant predictor at the
.01 level was globally normalized cerebral metabolic rate for glucose (CMRgl) in the left
mid temporal gyrus (β=-5.936, p=.01). No PET variables were retained in the final
imaging model.
In terms of laterality, remarkable consistency was found in the final neuroimaging
model. For the right hemisphere, five brain structures were represented in the final model.
For the left hemisphere, five brain structures were also represented in the final model.
Hypothesis #5: Can ADLs and IADLs be used to predict conversion from MCI to
dementia? It is hypothesized that performance on tests of neuropsychological
functioning will be a better predictor of conversion than ADL performance.
FAQ total score (β=.123, p<.001) was a significant predictor at the .01 level using
ADNI diagnostic criteria. However, functional abilities were not retained in the final
model, whereas, measures of delayed episodic memory were. FAQ scores were
significantly poorer for converters (mean 7.63, SD 5.6, range 0-28) than for
nonconverters (mean 3.91, SD 4.6, range 0-27) at baseline (t[392]=-5.687, p<0.001).
Hypothesis #6: Can neuropsychiatric functioning be used to predict conversion from
MCI to dementia? It is hypothesized depression will yield the highest predictive
value of any behavioral abnormality.
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Using ADNI criteria, no neuropsychiatric variable was a significant predictor at the
.01 level: GDS (β=.205, p=.475) and NPI (β=.042, p=.800).
Hypothesis #7: Can data from neuropsychological testing, demographic variables,
biomarkers, brain imaging, ADLs, and neuropsychiatric functioning be used to
construct a statistical model that predicts conversion from MCI to dementia with a
high level of accuracy? Furthermore, can this model be used to predict conversion
from MCI to dementia better than predictions made from any single variable or
variables from any factor groups (i.e., neuropsychological testing, demographic
variables, biomarkers, and brain imaging)?
In total, 13 variables (see Table 11) were retained in the final model (pseudo R2=.61,
ROC=.93) using the ADNI hand selected (see Statistical Analyses section) method
(ADNI hand selected model). A large proportion of variance was accounted for by the
equation, and area under the curve was good. Optimal cutting scores for predicted values
generated by the equation achieved sensitivity of .94 and specificity of .79 for a positive
predictive value of .66 and negative predictive value of .99. For lower equation scores,
sensitivity increased at the cost of specificity. For higher equation scores, specificity
increased at the cost of sensitivity.
Hypothesis #8: What diagnostic criteria can be used to construct an optimal
screening model?
For example, does a 1.0 or 1.5 SD cutoff using age- and education-adjusted scores on
tests of neuropsychological functioning yield more acceptable inclusion rates in
application of the screening model? Also, does using premorbid intelligence increase
the psychometric properties of a screening model? Finally, does allowing for some
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minor difficulties with ADLs yield a more optimal screening model? It is
hypothesized that using a 1.0 SD cutoff will be preferable to using a 1.5 SD cutoff,
that taking premorbid intelligence into account will increase the psychometric
properties of the screening model, and that allowing for some minor trouble with
ADLs will further increase the psychometric properties of a screening model.
The number and percentage of patients identified as normal, MCI, and mild AD
using each classification system can be found in Table 12. For each classification
system, statistical models were constructed to predict conversion from MCI to dementia
(see Table 7 for a detailed description of diagnostic criteria used for each classification
system). Two models were constructed for ADNI criteria using different methods: a
backward elimination method (ADNI backward elimination model) and a hand selected
method (ADNI hand selected model) (see the statistical analyses section for a detailed
description of the methods used to construct these two models). For the backward
elimination model (Table 13), 11 variables were retained in the final model (pseudo
R2=.50, ROC=.91). For the hand selected model (Table 11), 13 variables were retained
in the final model (pseudo R2=.61, ROC=.93). For Model #1 (Table 14), 23 variables
were retained in the final model (pseudo R2=.74, ROC=.97). For Model #2 (Table 15),
12 variables were retained (pseudo R2=.77, ROC=.97) in the final model. For Model #3
(Table 16), 6 variables were retained (pseudo R2=.41, ROC=.88) in the final model.
Cutting scores for predicted values generated by each equation with sensitivity of
.90 were associated with specificity of .80 for the ADNI hand selected model, specificity
of .71 for the ADNI backward elimination model, specificity of .90 for proposed model
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#1, specificity of .95 for proposed model #2, and specificity of .76 for proposed model
#3.
Final equations for each model were compared across each diagnostic system (see
Tables 17 and 18). For example, how well does the ADNI hand selected model perform
for patients identified as MCI using proposed criteria #1, and so on. Table 17 lists the
results of a series of binary logistic regressions. As can be seen, with the exception of the
ADNI backwards elimination model, each resulting model score was a significant
predictor of conversion using the associated classification system. For example, the
ADNI hand selected model was a significant predictor of conversion using ADNI
diagnostic criteria, model #1 was a significant predictor of conversion using proposed
criteria #1, model #2 was a significant predictor of conversion using proposed criteria #2,
and model #3 was a significant predictor of conversion using proposed criteria #3. The
only model that was a significant predictor at the .01 level across classification systems
was Model #1. It was a significant predictor using ADNI diagnostic criteria (β=6.032,
p<.001) and using proposed criteria #3 (β=3.558, p=.002). Model #1 trended towards
significance using proposed criteria #2 (β=9.190, p=.051). In Table 18, pseudo R2 and
AUC was examined across diagnostic system. Similar to the results listed in Table 17,
Model #1 appears to be the best performing model across diagnostic classification
systems.
When only allowing for “essentially normal” ADLs (defined as 0-1 on the FAQ),
108 patients were classified as MCI at baseline. Of these patients, 35 converted to
dementia. This resulted in an unacceptably restrictive model.
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Follow-Up Analyses:
Evaluating CSF Homocysteine at the Univariate Level
Homocysteine CSF level was not predictive of conversion from MCI to dementia
(β=.041, p=0.134).
Constructing the Most User-Friendly Equation for Neuropsychologists
For this model, only raw scores for major neurocognitive indices (e.g., AVLT
Total, BNT Total, etc.) and daily functioning were used. In total, six variables were
retained in the final model (see Table 19). A pseudo R2 of .22 and ROC of .81 were
observed. The optimal cutting score of -3.32 achieved sensitivity of .82 and specificity of
.68. For lower equation scores, sensitivity increased at the cost of specificity. For higher
equation scores, specificity increased at the cost of sensitivity.
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DISCUSSION

In the current study, diagnostic criteria for MCI and the ability of factors from
several categories (i.e., demographic, neurocognitive, functioning, imaging, biomarker,
and behavioral) to predict conversion from MCI to dementia were examined. Although
having been significantly transformed since their inception, it was demonstrated through
a review of the literature that current MCI diagnostic criteria are limited. First, as
currently written, these criteria are reliant on human judgment. However, human
judgment is subject to numerous factors that compromise its efficacy (Wedding & Faust,
1989) and render it suboptimal to judgments based on equations derived from statistical
analyses (Dawes, 2005; Dawes, Faust, & Meehl, 1989; Garb, 1994; Goldberg, 1965;
Goldberg, 1968; Goldberg, 1970; Grove et al., 2000; Marchese, 1992; Meehl, 1954;
Meehl, 1984; Sines, 1971; Wiggins, 1981). Second, multiple diagnostic criteria are
available so different criteria are being used by different clinicians. Third, as currently
written, all available criteria are somewhat ambiguous and can be applied in different
ways. For example, whereas one clinician judges impairment to be 1.5 SD below the
mean, another clinician may judge impairment to be 1.0 SD below the mean.
Consequently, error variance is introduced and has led to widely varying estimates of
incidence, prevalence, and conversion.
Although eight hypotheses were explored in the current study, each of the first six
hypotheses were constructed to lead up to the final two overarching hypotheses: MCI
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diagnostic criteria can be modified in a manner that removes much of the necessity of
using human judgment and a statistical equation can be constructed to predict conversion
from MCI to dementia with a high degree of accuracy. Results of the current study
supported these two hypotheses. First, it was demonstrated that MCI diagnostic criteria
could be modified in a manner that lessens the reliance on human judgment but also
enhances the ease with which MCI diagnostic criteria can be utilized and applied.
Second, it was demonstrated that an equation could be constructed using regression
modeling that predicts conversion from MCI to dementia with a high degree of accuracy.
Although this finding was consistent across varying applications of diagnostic criteria,
the model that demonstrated the best level of predictive power was the model using (1)
intact general cognitive functioning, (2) a 1.0 SD cutoff on one or more cognitive
domains, and (3) an allowance for some level of functional impairment. This finding was
consistent with a priori expectations.
For MCI to truly represent its conceptual base—as a predementia syndrome with
an etiology commensurate to dementia—the diagnostic criteria should be constructed in
such a way that a high number of people diagnosed with MCI go on to develop dementia.
In this paper, an attempt was made to redefine the diagnostic criteria currently available
for MCI. However, the two overarching hypotheses are composed of variables
representing a number of different classes (i.e., demographic, neurocognitive, functional,
imaging, biomarker, and behavioral variables), and each of these parts is represented by
the other six research hypotheses. In the sections that follow, each of these parts (i.e.,
“building-block” hypotheses) will be discussed with rationale pertaining to the reasoning
behind the hypothesis formulation. In ADL and IADL performance, for example, a priori
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expectations stated that both a screening and conversion model would be aided by aspects
of functional ability. Thus, daily functioning was expected to be a variable with a unique
contribution to conversion when examined in isolation from variables in other categories
and also to combine with variables from other categories to make an effective prediction
model. Thus, these parts or “building-block” hypotheses (e.g., functional ability) were
analyzed in a step-by-step fashion and used to build-up to the two overarching
hypotheses. Without including these “building-block” steps as a point of reference, the
main points (i.e., overarching hypotheses) could not be fully discussed. In the sections
that follow, each of the eight hypotheses evaluated in this paper will be discussed. The
final two hypotheses reflecting the two main points of this study will be discussed in
terms of their contributing parts or building-blocks. A discussion of the limitations of
this study and potential future directions of research will follow. Finally, clinical and
research implications of the findings outlined in this study will be discussed and followed
by a brief conclusion.
Hypothesis #1: Can demographic factors be used to predict conversion from MCI to
dementia? It is hypothesized that the female gender and low education will yield the
highest predictive values.
Education
It was expected in the current study that education would serve as a protective
factor from conversion. Contrary to this expectation, however, education was not
observed to protect a person with MCI from converting to dementia. These results seem
to indicate that once domain specific impairment is present education no longer functions
as a protective factor. These results also indicate that with a threshold of cognitive
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impairment education no longer protects against future general cognitive impairment
and/or functional impairment. One of two explanations seems likely. First, once a
person is impaired in at least one cognitive domain, the mitigating aspects of a cognitive
reserve are all but extinguished. Thus, domain specific impairment renders the protective
qualities of education inert regardless of level of education. Second, to be classified as
exhibiting domain specific impairment, a person with a high level of education is already
more impaired than a person with a low level of education and already utilizing
considerable cognitive reserve to not be considered demented. Thus, whatever higher
level of reserve was present has now been exhausted or almost exhausted. Exploring the
validity of these two explanations was beyond the scope of this study. However, the
incorporation of previous research results into the framework offered by the current study
may offer some clues.
The bulk of studies available in the literature examine the protective factors of
education as they relate to a healthy older adult eventually developing dementia (Brayne
et al., 2010; Del Ser et al., 1999; Letenneur et al., 1999; Ott et al., 1995; Stern et al.,
1994; Valenzuela et al., 2008; Valenzuela and Sachdev, 2006), but conversion is not
development. For development studies, a person is recruited as a healthy older adult and
followed until he/she is diagnosed with dementia. In this scenario, an unbroken timeline
is present from relative good cognitive health to cognitive and functional impairment
characteristic of dementia. Thus, without a point of reference in the timeline, education
could be functioning as a protective factor from any aspect of dementia including domain
specific cognitive impairment, general cognitive impairment, functional decline, or all
three. For conversion, on the other hand, some level of domain specific cognitive
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impairment has already occurred, thereby, inserting a reference point in the timeline of
normal cognition to development of dementia. Thus, only general cognitive impairment
and functional decline are left as possible factors from which education could serve as a
protective factor.
In contrast to the finding outlined above that states education does not protect a
person with MCI from converting to dementia, the results of numerous longitudinal
studies have indicated that education is a protective factor against developing dementia
(Letenneur et al., 1999; Ott et al., 1995; Stern et al., 1994). The exact mechanism for this
protection is unknown and two different hypotheses have been proposed. In one
hypothesis, education is thought to protect the brain from the underlying pathologies
associated with dementia (Del Ser et al., 1999). In the alternate hypothesis, people with
more education are thought to have a better capacity to compensate for the neuropathic
changes associated with dementia (Valenzuela et al., 2008; Valenzuela and Sachdev,
2006). In other words, people with more education will have brain atrophy comparable
to people with less education but will be better able to compensate for this atrophy
because of a greater cognitive reserve.
In an attempt to better characterize the mechanism that education has on dementia
acquisition, Brayne and colleagues (2010) examined the association between education
and brain pathology at death. Results indicated that although associated with decreased
dementia risk and greater brain weight, education was not associated with a decrease in
neuropathology. Thus, education did not protect people from atrophy but did mitigate the
clinical expression of dementia. Regardless of the mechanism of protection, the more
education a person had the less likely he/she was to develop dementia. However, in
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contrast to expectations, the results of the current study indicated that this trend does not
hold for people already exhibiting cognitive impairment characteristic of MCI, thereby,
supporting the notion that domain specific impairment exhausts the protective aspects of
education.
Gender
Although controversy exists about overall gender difference in dementia
development, rates of AD are higher among females than among males at some point in
the aging process. Given that aMCI patients were included in the ADNI database
combined with knowledge that women have a greater risk of developing AD, it was
hypothesized that females would convert at a higher rate than males. However, this
assumption was not supported by the results of the current study, and rates of conversion
did not differ significantly between females and males. The likely explanations for this
finding are identical to the reasons given for the lack of an effect of education. Namely,
the point of interest in the timeline is actually mild cognitive impairment as opposed to
dementia. However, sample specific factors may also be contributing which include age
of the sample (mean of 75 years) and the inclusion of almost twice as many males than
females.
In regards to any dementia type, previous studies on incidence rates in males and
females are mixed. Results of some studies indicate that females are more likely to
develop dementia than males with gender differences becoming more pronounced for
people over the age of 85 (Anderson et al., 1999; Brayne et al., 1995; Clark et al., 1996;
Fratiglioni et al., 1997; Morgan et al., 1993; Yoshitake et al., 1995). But results of other
studies have noted a lack of significantly different incidence rates of dementia between
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females and males (Bachman et al., 1993; Ganguli et al., 2000; Letenneur et al., 1994;
Paykel et al., 1994; Rocca et al., 1998). In contrast to conversion to any dementia type,
the focus of the current study was conversion specifically to AD. In the AD literature,
results consistently note that development becomes more prevalent in females than in
males at some point during the aging process (Brayne et al., 1995; Fratiglioni et al., 1997;
Hagnell, Ojesjo, & Rorsman, 1992; Letenneur et al., 1994). Thus, it was expected that
this trend would extend from development to conversion. However, as noted above, this
expectation was not found.
Hypothesis #2: Can neuropsychological testing be used to predict conversion from
MCI to
dementia? It is hypothesized Logical Memory – II will yield the highest predictive
value of any measure.
In the current study, an evaluation of neurocognitive results indicated that four
variables were significant predictors of conversion when analyzed in combination with
all other neuropsychological variables (see Table 10). As can be seen, all of these
variables relate to three cognitive domains: (delayed) memory, language, and processing
speed. Next, using only neuropsychological variables, an equation was constructed to
identify people with MCI who would eventually convert to dementia. The resulting
model accounted for roughly a quarter of variance. Moreover, its associated clinical
cutoff may provide clinicians with a useful tool when questions about conversion arise.
Using only a person’s neurocognitive profile, the resulting equation predicted conversion
from MCI to AD with modest accuracy. As expected, a test of delayed episodic memory
(i.e., Logical Memory – II) exhibited the highest predictive power of any

55

neuropsychological variable. Other measures of episodic memory as well as measures of
recognition memory, executive functioning, language, attention, and processing speed
were also retained in the final model (Table 9). The optimal cut-score for this equation
was noted as obtaining sensitivity of 80% and specificity of 71%. The equation along
with examples of using the equation can be found in Table 9 and Appendix #1. In
addition, an Excel spreadsheet and detailed instructions for working this equation can be
obtained from the first author of this study.
Like in the current study, the association between conversion from MCI to AD
and neuropsychological variables has previously been examined. Consistent with the
results of this study, results of prior studies show that neurocognitive functioning is a
significant predictor and that memory impairment is the most powerful univariate
predictor of conversion from MCI to AD (Aggarwal et al., 2005; Blacker et al., 2007;
Devanand et al., 2008; Gomar et al., 2011; Tabert et al., 2006; Tierney et al., 1996).
Impairments in executive functioning (Blacker et al., 2007; Gomar et al., 2011; Tabert et
al., 2006; Tierney et al., 1996) and processing speed (Aggarwal et al., 2005; Gomar et al.,
2011) have also been shown to significantly increase conversion risk. These results fit
well with the results outlined in the current study. In addition, older adults with impaired
memory as well as impaired functioning in at least one other cognitive domain are shown
to be more at risk of conversion over a three-year period (Tabert et al., 2006). These
findings also assimilate well with the results of the current study which demonstrated that
impairment in three cognitive domains (i.e., episodic memory, language, and processing
speed) was particularly predictive of conversion over a one-year period. However, the
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model and resulting equation offered in the current work expand upon these findings and
present the opportunity for enhanced clinical utility.
Regression models have been detailed prior to the current study. Moreover, like
in the current study, regression models have been utilized to determine the ability of
numerous neuropsychological variables to predict conversion. In a sample of 218 older
adults diagnosed with MCI, measures of episodic memory, semantic memory, working
memory, and processing speed were all noted as univariate predictors of conversion
(Aggarwal et al., 2005) with performance on a measure of visuospatial ability not being
associated with conversion. When all variables were analyzed together, only episodic
memory and processing speed remained significant predictors with episodic memory the
strongest predictor at both the univariate and multivariate level. Older adults with poorer
episodic memory were twice as likely to convert when compared with older adults who
have diminished performance in another cognitive domain. Moreover, poorer baseline
episodic memory was predictive of a more rapid overall decline and an increased risk of
conversion over a 10-year period. A decline in a cognitive domain other than memory
was only predictive of conversion for the year immediately following onset of singledomain impairment. Executive functioning (Blacker et al., 2007; Tabert et al., 2007;
Tierney et al., 1996) has also been observed to significantly predict conversion and when
combined with performance on a measure of delayed visual memory has been noted as
achieving sensitivity of 76% and specificity of 94% (Tierney et al., 1996). Although
these findings add to the research literature and are useful in a clinical context, the ability
of clinicians to apply this information is limited. Thus, the detailing of a statistical model

57

in the present work offers an exciting expansion of regression models for the prediction
of conversion from MCI to dementia.
Hypothesis #3: Can biomarkers collected from CSF, urine, or blood be used to
predict conversion from MCI to dementia? It is hypothesized that homocysteine levels
will yield the highest predictive value.
The term “biomarker” refers to entities that are associated with a disease through
concentration, presence, and activity (Anoop, Singh, Jacob & Maji, 2010). In the current
study, the only biomarker collected from CSF, urine, and blood/plasma to be a significant
predictor of conversion was Aβ40. Aβ or amyloid-beta is a term used to describe
peptides of 36-43 amino acids. Aβ40 has been shown to be present in both senile plaques
as well as vascular amyloid and both senile plaques and vascular amyloid are hallmarks
of dementia (Castano et al., 1996). Therefore, given the association senile plaques and
vascular amyloid have with dementia and AD (Castano et al., 1996), it is not surprising
that some form of amyloid-beta was able to predict conversion from aMCI to AD.
In contrast to a priori expectations, homocysteine CSF level was not significantly
related to conversion. A potential reason that a discrepancy exists between the findings
of the current study and those noted by Mattsson and colleagues (2009) is that AD
biomarkers in the latter study were examined at the univariate level. Thus, homocysteine
CSF level was analyzed at the univariate level for a follow-up analysis in the current
study. Once again, findings were contrary to those by Mattsson and colleagues (2009),
and homocysteine CSF levels were not predictive of conversion even when analyzed in
isolation. As noted by Jack et al. (2010) a possible reason for the above mentioned
discrepancy may be one of timing because different biomarkers may have different
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predictive values at varying times in the progression of a disease. For example, in MCI,
progression during the first year may be highly associated with baseline markers of
neurodegeneration. However, progression may be better accounted for by markers of
brain amyloid over a longer longitudinal course (Dickerson & Wolk, 2013).
Earlier in this paper, a brief review of CSF, urine, and blood biomarkers in AD
was conducted. As was evident in this review, most statistically relevant AD biomarkers
have been discovered in CSF as opposed to urine and blood/plasma. Thus, studies have
also been conducted to determine if the examination of CSF for conversion biomarkers is
useful. However, most of these studies included small samples examined only at a single
site. In a large-scale study of 750 MCI patients in 12 centers located in the United States
and Europe, the ability of CSF biomarkers to predict incipient AD in patients with MCI
(Mattsson et al., 2009). Results indicated that three CSF biomarkers (i.e., Aβ42, P-Tau,
and T-Tau) could be used to predict conversion with good accuracy. Less accuracy was
reported in studies utilizing smaller samples examined at a single site. The authors also
noted that some of the variability in the literature is present because the procedures used
for designating biomarker cutoffs as well as the cutoffs themselves varied considerably
from study to study. Thus, optimal clinical cut-scores have yet to be established for
biomarker data and clinical judgment appears to be an issue in the study of these
variables. Regardless, given that biomarkers of conversion were noted in a large-scale
study, it was expected that the current results would fundamentally match these earlier
findings. However, this expectation was not met.
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Hypothesis #4: Can brain imaging be used to predict conversion from MCI to
dementia? It is hypothesized hypometabolism in the hippocampal brain area will
yield the highest
predictive value.
In the current study, an evaluation of MRI results indicated that six areas were
significant predictors of conversion when analyzed in combination with all other MRI
variables: cumulative temporal lobe atrophy, left hippocampal volume, right precentral
cortex volume, right middle orbital grey matter volume, right posterior cingulum grey
matter volume, left superior temporal gyrus volume, and right cerebellum grey matter
volume (see Table 10). As expected, with the exception of right cerebellum grey matter
volume and right posterior cingulum volume, all of these areas are located in the frontal
or temporal lobes and consistent with previous imaging studies evaluating conversion
from MCI to dementia (Devanand et al., 2007; Whitwell et al., 2008).
For PET, only glucose consumption in the left middle temporal gyrus was a
significant predictor of conversion when analyzed in combination with all other PET
variables. However, this variable was not retained in the final imaging model. Contrary
to a priori hypotheses, reduced glucose consumption in the hippocampus was not the
strongest imaging predictor. In this sample, cumulative temporal lobe atrophy exhibited
the greatest predictive value when compared to PET and MRI variables.
Next, an equation was constructed to identify people with MCI that would convert
to dementia using only imaging variables. This model accounted for approximately a
third of variance in conversion, and the resulting equation (see Table 10) predicted
conversion from MCI to AD with modest accuracy. The optimal cut-score for this
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equation (-2.04) was noted as obtaining sensitivity of 85% and specificity of 71% via
ROC analysis. The equation along with examples of using the equation can be found in
Table 10 and Appendix #2. In addition, an Excel spreadsheet and detailed instructions
for working this equation can be obtained from the first author of this study.
As in the current study, the utility of using imaging results to predict conversion
in MCI patients has previously been examined. In one such study, 139 people with MCI
and 63 healthy controls were scanned using MRI and followed for five years (Devanand
et al., 2007). Consistent with the results of the current study, temporal structures could
be used to classify sample groups. At baseline, Devanand and colleagues (2007) noted
that hippocampal and entorhinal cortex volumes were largest in healthy controls,
intermediate in nonconverters, and smallest in converters. Relative volumes of these
same brain areas were also found to significantly predict time to conversion. In another
study, 63 people with aMCI and 63 demographically matched controls were scanned
using MRI and followed for three years (Whitwell et al., 2008). When compared to
controls, MCI patients that converted to dementia had bilateral loss affecting the medial
and inferior temporal lobe, the temporoparietal association cortex, and the frontal lobes.
When compared to nonconverters, MCI patients that converted to dementia had MRI
profiles strikingly similar to those of the current study. Also in the study by Whitwell
and colleagues (2008), greater loss was noted in the medial and inferior temporal lobes,
the temporoparietal cortex, the posterior cingulate, the precuneus, the anterior cingulate,
and the frontal lobes.
In contrast to MRI, FDG-PET studies in MCI are controversial because reduced
cerebral metabolic rate of glucose consumption may not be detectable outside the
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hippocampal formation in patients with minimal impairment (Schuff & Zhu, 2007).
However, in a small PET study, cortical changes to glucose metabolism were observed in
a group of MCI patients that were scanned twice over a year (Drzezga et al., 2003).
Glucose consumption was lower in the posterior cingulate cortex and precuneus for
converters than it was for nonconverters at baseline. At follow-up, glucose consumption
was lower in bilateral prefrontal areas, and reduced consumption had progressed in the
posterior cingulate cortex. This finding was not supported by the results of the current
study since only hypometabolism in the left middle temporal gyrus was predictive of
conversion at the .01 level.
Hypothesis #5: Can daily functioning be used to predict conversion from MCI to
dementia? It is hypothesized that performance on tests of neuropsychological
functioning will be a better predictor of conversion than daily functioning.
Consistent with a priori expectations, functional abilities significantly predicted
conversion. Interestingly, although functional abilities were poorer for converters at
baseline, nonconverters also demonstrated multiple functional decrements even when
utilizing the FAQ—a means of evaluation less objective than a performance-based
measure. Thus, it not only appears that functional impairment is a characteristic of MCI,
but it also appears that a continuum exists between MCI and dementia in regards to
functional impairment. Also consistent with prior expectations, delayed episodic
memory was a stronger univariate predictor of conversion than functional ability.
Prior research has shown that although basic ADLs (i.e., eating, dressing, bathing,
etc.) remain preserved in people with mild cognitive impairments, higher-order IADLs
(i.e., financial and medication management, using public transportation, interacting with
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technology, etc.) are often subtly impaired (Winblad et al., 2004). But as highlighted
earlier, diagnostic criteria related to everyday functioning in MCI are (see Tables 1 and 3)
constructed in a manner that assumes delineation between virtually intact functional
abilities for MCI and impaired functional abilities for dementia. However, the results of
this study do not support this delineation as both converters and nonconverters presented
with functional decrements. In addition, prior research also points to this delineation as
problematic for a number of reasons (Goldberg et al., 2010). First, medical and
psychiatric conditions that are reliably associated with cognitive changes are, in turn, also
reliably associated with changes in everyday functioning (Goldberg et al., 1990; Heaton
et al., 1994). Second, given that cognitive decline is associated with changes in everyday
functioning, the cognitive impairments characteristic of MCI should exact a graduated
cost on function (Goldberg et al., 2010).
In addition to issues with the current diagnostic criteria, the evaluation of daily
functioning in MCI is flawed because standardized measures sensitive to minor
functional changes are not commonly utilized (Goldberg et al., 2010). At present, the
most common method for garnering information about the everyday functioning of a
patient is to interview a close relative. However, the reliability of this method suffers
because of halo effects, memory lapses, and limited knowledge that can lead to an
overestimation of the functional capacity of MCI patients (Loewenstein et al., 2001).
One way to increase the utility of functional evaluations would be to introduce the use of
performance-based measures into standard neuropsychological test batteries. Recent
research has demonstrated that patients with MCI show significantly compromised
functional abilities when evaluated with performance-based measures, and this trend
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extends to patients identified as having intact functioning by family members (Goldberg
et al., 2010).
Unfortunately, performance-based measures were not utilized as part of the ADNI
study. However, the measure utilized in ADNI (i.e., FAQ) was designed to evaluate a
number of higher-order IADLs and produce a total score that can be compared between
patients. Given that patients with MCI likely demonstrate functional impairment on a
continuum with dementia, it was assumed that differences would be present and
statistically discernable among patients
who convert to dementia and patients who do not convert to dementia. This expectation
was supported by the findings of this study.
Hypothesis #6: Can neuropsychiatric functioning be used to predict conversion from
MCI to dementia? It is hypothesized that depression will yield the highest predictive
value of any behavioral abnormality.
Contrary to expectations, results of the current study showed that depression was
not predictive of conversion to dementia in this sample of people with MCI. Of all
psychiatric conditions, depression’s relationship with cognitive impairment is by far the
most widely studied and discussed. Up to 50% of all people living with AD have
significant symptoms of depression and up to 20% meet diagnostic criteria for major
depression (Wragg & Jeste, 1989). Although results of a meta-analysis demonstrate that
depression is a risk factor for dementia (Jorm, 2001), some studies have not noted an
association between depression and dementia (Becker et al., 2009; Fassbender et al.,
1999; Hendersen et al., 1997). Moreover, the role of depression as a risk for dementia is
not well understood, and multiple hypotheses explaining the association are found in the
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literature (Jorm, 2001). These hypotheses include: (1) depression is an early prodome of
dementia, (2) depression brings forward the clinical aspects of dementia, and (3)
depression leads to hippocampal damage.
The expectation that depression would be predictive of conversion was made
despite its contradiction to an earlier study by Panza and colleagues (2008) that found no
association between depression and conversion in a sample of 2,963 community-dwelling
adults between the ages of 65-84 who were followed for 3.5 years. Moreover, results
also showed that no socio-demographic or vascular risk factors could be used to modify
the association between depression and conversion. However, in a more homogenous
sample that utilized hospital patients, depression was able to predict conversion from
MCI to dementia (Modrego and Ferrandez, 2004). The reason it was hypothesized that
results of the current study would more closely match the findings of Modrego and
Ferrandez (2004) than the findings of Panza et al. (2008) were twofold. First, in the
2008 study by Panza and colleagues, only 10% of the sample of people with MCI
converted to dementia. Thus, it was believed that the sample likely represented a group
of MCI patients more cognitively advanced than normal. Second, it was believed that the
sample of hospital patients utilized by Modrego and Ferrandez (2004) would likely
represent a group of people with more cognitive impairments and higher rates of
depression than the people included in the ADNI sample.
As documented earlier, results of a meta-analysis noted that depression is a
significant risk factor of dementia development (Jorm, 2001). Interestingly, current study
findings are in contrast to this association and seem to indicate that this risk is minimized
once cognitive impairment is present. The most likely reason for this dissociation is that

65

studies of dementia development follow healthy controls with normal cognitive
functioning while studies of conversion follow adults with some level of cognitive
impairment. Thus, the current results and findings of Panza and colleagues (2008) seem
to indicate that depression is a risk factor for dementia simply because it is a risk factor
for cognitive impairment. In addition, these results may indicate that the presence of
significant cognitive impairment dulls the additive effects of factors with lesser
associations to dementia development (e.g., gender, education, depression). However,
the investigation of this theory is beyond the scope of this study. Other potential reasons
to explain the lack of association between conversion and depression relate to the ADNI
sample itself, namely, that levels of depression were low in the ADNI sample, that the
use of a self-report measure of depression lacked sensitivity, that follow-up was limited
to 2-years, and that some people with depressive symptoms were receiving treatment for
depressive symptoms.
Hypothesis #7: Can data from neuropsychological testing, demographic variables,
biomarkers, brain imaging, ADLs, and neuropsychiatric functioning be used to
construct a statistical model that predicts conversion from MCI to dementia with a
high level of accuracy? Furthermore, can this model be used to predict conversion
from MCI to dementia better than predictions made from any single variable or
variables from any factor groups (i.e., neuropsychological testing, demographic
variables, biomarkers, and brain imaging)?
In the current study, the following variables were significant predictors of
conversion when all categories of variables were taken into account (Table 11): AVLT
Total Intrusions for Trial 2, BNT Total semantic cues, cumulative temporal lobe atrophy,
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right precentral grey matter, and right front mid orbital grey matter. The resulting
equation accounted for approximately two-thirds of variance and predicted conversion
from MCI to AD with a high level of accuracy. Moreover, this model was able to predict
conversion from MCI to dementia better than predictions made from any single variable
or variables from any factor groups. The optimal cut-score for this equation (-2.11) was
noted as obtaining sensitivity of 94% and specificity of 79% for a positive predictive
value of 66% and negative predictive value of 99%. For people scoring above the
clinical cut-score of -2.11, the predictive value obtained from the equation indicated a
high risk of converting to dementia over the course of the following year, and this was
correct 66% of the time. For people scoring below or equal to -2.11, the value obtained
from the equation indicated a lower risk of conversion over the next year, and this was
correct 99% of the time. Examples of this regression-based model are provided in Table
11, and a guide for operating these types of equations can be found in the appendix.
Moreover, an Excel spreadsheet and instructions can be obtained from the first author of
this study that will aid in working the predictive equation.
To date, only a handful of studies have examined factors spanning a number of
different categories (e.g., demographics, biomarkers, imaging, and cognition) in
predicting conversion from MCI to dementia. In the first study of its kind, Jack and
colleagues (1999) followed 80 patients diagnosed with MCI for an average of
approximately 32 months. All 80 patients received an MRI of the head at baseline and
other testing. Of the 80 patients included in the sample, 27 converted to dementia. The
factor most capable of predicting conversion at the univariate level was baseline
hippocampal atrophy. Moreover, the addition of age, postmenopausal estrogen
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replacement, cognition (i.e., general cognitive functioning, verbal memory, attention, and
verbal fluency), APOE, history of ischemic heart disease, and hypertension did not
significantly increase the estimate of relative risk. However, results of another study
showed that general cognitive functioning, processing speed, and delayed verbal memory
had an estimated predictive accuracy of 79% (Fleisher et al., 2007). None of
hippocampal volume, ventricular volume, APOE4 genotype, and/or demographic
variables improved the predictive accuracy of the model. In contrast, more recent studies
have noted a combination of imaging and neuropsychological variables as possessing the
best predictive validity. For example, Devanand and colleagues (2007) found that a
combination of age, general cognitive functioning, delayed verbal memory, processing
speed, hippocampal volume, and entorhinal cortex volume best predicted conversion
from MCI to dementia. Similar findings were also noted by Gomar and colleagues
(2011). In this study, only delayed verbal memory and temporal lobe cortical thickness
remained significant at the multivariate level. As can be seen, later models have included
both cognitive and imaging variables to achieve the greatest level of predictive accuracy,
commensurate to the findings of the current study.
Hypothesis #8: What diagnostic criteria can be used to construct an optimal
screening model?
For example, does a 1.0 or 1.5 SD cutoff using age- and education-adjusted scores on
tests of neuropsychological functioning yield more acceptable inclusion rates in
application of the screening model? Also, does using premorbid intelligence increase
the psychometric properties of a screening model? Finally, does allowing for some
minor difficulties with ADLs yield a more optimal screening model? It is
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hypothesized that using a 1.0 SD cutoff will be preferable to using a 1.5 SD cutoff,
taking premorbid intelligence into account will increase the psychometric properties
of the screening model, and allowing for some minor trouble with ADLs will further
increase the psychometric properties of a screening model.
As can be seen in Table 12, the number of patients classified as normal were
strikingly similar across diagnostic systems. Relative consistency across diagnostic
system was also observed for patients classified as AD. The number of patients
identified as MCI and converting to dementia (see Table 12), however, varied across
diagnostic system because many patients were not able to be classified using proposed
diagnostic criteria. To retain a high level of consistency among diagnostic systems,
attempts were made to use ADNI criteria whenever possible. Consequently, the same
cutoffs on the MMSE and CDR used for ADNI classification were used for the proposed
diagnostic criteria as well. However, the introduction of a measure of daily functioning
and associated cutoff caused a considerable number of patients to be unclassifiable using
proposed criteria. As noted by Teng and colleagues (2010), a FAQ score >5
demonstrates good utility for differentiating AD from MCI. Thus, for proposed criteria,
this cut-score was utilized as a diagnostic criterion. However, a subsequent issue was
encountered when applying the criteria that included daily functioning because its
inclusion led to discrepancies among MMSE, CDR, Logical Memory – II, and FAQ
scores. For instance, using proposed criteria #1, a patient with an MMSE of 27, CDR of
0.5, Logical Memory – II score falling more than 1.0 SD below the mean, and FAQ score
of 6 would also be unclassifiable because the obtained FAQ score lies above the cutoff
proposed by Teng and colleagues (2010) when all other scores lie within the MCI range

69

according to ADNI criteria. It should be noted, however, when using only FAQ and
Logical Memory – II scores as diagnostic criteria, almost all of the unclassified patients
would have been classified as MCI, and the psychometric properties of the resulting
models were very similar to those listed in Table 18.
Neurocognitive Cutoff (i.e., 1.0 vs. 1.5 SD)
The percentages of patients who converted from MCI to dementia according to
each diagnostic system are listed in Table 12. However, because of the widely varying
estimates of conversion found in the literature, these percentages are not useful when
comparing the efficacy of the different screening models.
Although all subjects in the current study were part of the ADNI database, the
application of different diagnostic criteria essentially divided this one sample into four
samples: one sample using ADNI diagnostic criteria and three samples using proposed
diagnostic criteria. Thus, comparisons of performance measures (i.e., pseudo-R2 and
AUC) can be made across samples/diagnostic systems (see Table 18). When evaluating
the different diagnostic systems and associated models in this way, one cardinal rule must
be followed: pseudo-R2 and AUC for a model should not be considered in relation to the
sample from which they were derived. When evaluating the models in this manner, the
model derived using Proposed Criteria #1 (i.e., the model utilizing a 1.0 SD cutoff and
allowing for scores ≤5 on the FAQ) appears to have a slight advantage to the model
derived using Proposed Criteria #2 and a clear advantage to other models. In fact, the
model constructed using Proposed Criteria #1 was the best performing model whenever
this general rule was followed. Taken in combination with the observation that Proposed
Criteria #1 and Proposed Criteria #2 had the best pseudo-R2 and AUC in relation to the
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sample from which they were derived, it is clear that Proposed Criteria #1 yielded the
best screening model. Thus, it appears that a 1.0 SD cognitive cutoff is preferable to a
1.5 SD cutoff.
Daily Functioning
One method to evaluate the usefulness of the different diagnostic systems is to
compare the number of predictors used in the final conversion model. Across the five
models, the number of included predictors ranged from 11 to 23. Although still a large
number of predictors, it would be easier to work with a model containing 11 predictors
than it would be to work with a model containing 23 predictors. However, ease only tells
a small part of the story because performance of the model in predicting conversion is
much more important. Although these five models cannot be directly compared with
statistical methods, statistics can be used for evaluative purposes. For example, the
psychometric properties of the models in relation to their specific diagnostic criteria can
be compared (see Table 18). When considering pseudo-R2 and AUC as performance
measures, Model #1 and Model #2 have a clear advantage and are almost equal in utility.
Interestingly, both of these models were derived from diagnostic systems that took into
account scores from a measure of daily functioning (i.e., FAQ). Thus, from this limited
method of comparison, it appears that allowing for some decrements to daily functioning
(i.e., allowing for scores ≤5 on the FAQ) improves the utility of a diagnostic
classification system.
Premorbid Intelligence
Contrary to a priori hypotheses, premorbid intelligence did not appear to increase
the efficacy of a screening model in this cohort of people with MCI. Evidence of this
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conclusion comes from two sources. First, Proposed Criteria #3 was the only set of
diagnostic criteria that took estimates of premorbid intelligence into account. However,
the model constructed using Proposed Criteria #3 produced the poorest performance
measures when considered in relation to the sample from which they were derived (see
Table 18). Moreover, the model constructed using Proposed Criteria #3 was arguably the
worst performing model across the different samples. Second, evidence for the lack of
utility of premorbid intelligence can be found in the individual neuropsychological
predictors that comprise the different models. For each neuropsychological measure,
three values were considered: raw score, normative-corrected z-score, and normativecorrected z-score in relation to estimated premorbid IQ. Interestingly, not even a single
neuropsychological variable that took into account estimated premorbid IQ was retained
in the neuropsychological model (Table 9) or any model derived utilizing ADNI and/or
proposed diagnostic criteria (Tables 11 and 13-17).
Follow-Up Analyses: Constructing the Most User-Friendly Equation for
Neuropsychologists
To a clinician, the model that would be the easiest to use would be the model with
the most obtainable data. For neuropsychologists, this model would be comprised of raw
scores obtained from measures that can be administered during a brief
neuropsychological evaluation. Thus, an equation was constructed using only daily
functioning and raw scores from core indices of neuropsychological measures
administered as part of the ADNI study. The resulting equation predicted conversion
from MCI to AD with modest accuracy, and the optimal cut-score for this equation (3.32) was noted as obtaining sensitivity of 82% and specificity of 68% via ROC analysis.
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To increase the facility of this model, an Excel spreadsheet has been provided that will
calculate the predicted score for a patient. Although an example, this spreadsheet
demonstrates how prediction equations can be distributed for widespread clinical use.
Directions for using the attached Excel spreadsheet are included in a separate document
and are as follows:
1.

Enter FAQ Score into cell A2 (highlighted in green).

2.

Enter Logical Memory – II Total into cell B2 (highlighted in green).

3.

Enter Clock Drawing Total Score into cell C2 (highlighted in green).

4.

Enter AVLT Delayed Recall Total Score into cell D2 (highlighted in green).

5.

Enter the seconds needed to complete Trails A into cell E2 (highlighted in green).

6.

Enter ADAS-Cog Total Score into cell F2 (highlighted in green).

7.

Predicted Score for the patient will appear in cell G1 (highlighted in red).

8.

Compare the predicted score appearing in cell G1 to the cut-score of -3.32.

9.

Scores >-3.32 indicate an increased risk of conversion.

10.

Scores ≤-3.32 indicate a decreased risk of conversion.
Limitations and Future Directions
Despite the considerable findings presented in the current study, there are a

number of limitations and future directions to be considered. First, like most other
multisite University-based studies, the current sample may not completely represent the
population from which is was drawn. Patients needed to agree to participate in several
hours of testing, have an MMSE ≥24, and not have other central nervous system
disorders. This in all probability yields a select MCI group, and these results might not
generalize to all patients with MCI. Moreover, ADNI subjects represented a highly

73

educated, Caucasian cohort of older adults with MCI. Thus, the resulting models
highlighted in this paper may not translate well to other races and groups with less
education. Second, for people to be included in this study sample, a subjective memory
complaint was required. However, subjective memory complaints are a poor indicator of
actual memory impairment (Reid & Maclullich, 2006) and may exclude some people
with MCI. Thus, future studies should not require a subjective memory complaint for
inclusion. Third, a score of ≥24 on the MMSE was required for study inclusion;
however, the MMSE has a number of limitations that include age and education bias,
limited focus on memory, and lack of an executive functioning component (Lorentz et al.,
2002; Kahokehr et al., 2004; Brodaty et al., 2006). Fourth, as previously discussed, the
assessment of functional decline in MCI is flawed. Although a measure evaluating
several aspects of higher-order functional skills was utilized in the current study,
performance-based measures of daily functioning are superior and should be included in
future studies. Fifth, a large number of variables were considered when developing the
models designed to predict conversion from MCI to dementia. Because of the number of
variables, multiple steps had to be conducted prior to developing a final model for each
diagnostic system. Future studies should limit the number of variables to ensure that the
best predictors are included in conversion models. For example, since a dearth of zscores were retained in final models, the number of neuropsychological variables can be
reduced by only considering raw scores. In relation to imaging, no PET variables were
retained in a final model and a preponderance of retained imaging variables related to
frontotemporal structures. Thus, imaging variables can be significantly reduced by
limiting consideration to MRI results of frontotemporal structures. Sixth, although steps
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were taken to cross validate the models outlined in the current study, cross validation
with independent studies is clearly needed. Moreover, clinical validation is necessary
before conversion models can be used in clinical decision-making. Seventh, the only
type of MCI considered in the current study was aMCI. However, other MCI types
should be examined in future studies to investigate the utility of these findings in other
MCI types as well as to develop models for MCI types other than aMCI. Eighth,
conversion was defined as progressing from MCI to dementia. However, in the current
study, dementia was defined according to diagnostic criteria for AD. Future studies
should evaluate conversion for other dementia types including both vascular dementia
and frontotemporal dementia. Also, pathological confirmation is needed to ensure that
patients classified as converting from MCI to AD did not convert to a dementia type
other than AD. Finally, future studies should compare clinical judgment to the equations
outlined in this study.
Implications
To date, although studies have been conducted that are useful to clinicians, no
studies have provided clinicians working with people with MCI a viable tool to predict
which patients will convert to dementia. As a clinician, it is useful to know that a patient
with MCI exhibited impairment on tests of episodic memory and that MRI results
indicated mild diffuse cerebral atrophy because research has demonstrated that this
patient has an increased risk for progressive decline. However, albeit useful, this
information leaves a clinician in a precarious position. What should the patient and
his/her family be told when questions about conversion occur? At present, the clinician
can only answer these questions in vague terms.
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However, in the current study, an equation was constructed that can be applied in
clinical practice. This model and associated cut-score offers neuropsychologists, as well
as other health providers, an exciting opportunity. With this equation, a
neuropsychologist has the potential to answer questions about conversion with much
more certainty. Instead of giving vague answers, concrete probabilities based upon
empirical research can be provided. Moreover, regression based models and associated
equations have the potential to enhance the referral base of neuropsychologists and
expand their role on medical teams. At present, typical referral questions for
neuropsychologists working with older adults relate to diagnosis and differential
diagnosis. However, being able to give reliable and valid probabilities of conversion
rates has the potential to allow neuropsychologists the opportunity to provide
geriatricians, neurologists, and general practitioners a power tool when formulating
medication and treatment regimens for older adults. In regards to treatment, equations
like the one presented in this paper can help identify people with MCI due to AD versus
MCI due to a reversible condition. Therefore, treatments can be better personalized
based on the likelihood of a person’s developing dementia.
Beyond simply enhancing the usefulness of a neuropsychologist, studies of this
type have the potential to change the field of neuropsychology. At present, the decisionmaking process employed by neuropsychologists has several steps. First, medical
records are examined for the referral question and factors of interest. Second, the patient
and family are interviewed so a detailed medical and cognitive history can be obtained
with emphasis given to the onset and progression of cognitive and movement related
symptoms. Third, a test battery of varying length is chosen and administered. Fourth,
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scores on the measures comprising the battery are calculated, and performance is
considered in relation to demographically-matched peers. Fifth, these results are
considered in relation to findings garnered from the records’ review and interviews that
the neuropsychologist deems important. Seventh, the neuropsychologist conducts a
sometimes lengthy and exhaustive literature review in an attempt to compare the patient’s
profile in relation to empirical research. Finally, a diagnostic impression is rendered.
If this process appears inefficient and suboptimal, that is because it is. Further,
this process relies heavily on clinical judgment and places a clinician in the position to
violate numerous decision-making contraindications (e.g., overreliance on salient data,
human cognitive limitations, etc.). However, with regression models, many steps in this
process can be excluded, and the reliability and validity of diagnostic impressions
standardized and greatly enhanced. In addition, regression based models have the
potential to show which measures add incremental validity. Thus, test batteries can be
streamlined and tailored for possible differential diagnoses that were hypothesized (e.g.,
AD versus frontotemporal dementia versus vascular dementia) based upon the referral
question and records’ review. This likely means that test batteries can be shortened,
placing less stress and discomfort on the older adult patient and allowing the
neuropsychologist to see more patients. Finally, quantitative representations of brain
imaging should be utilized in clinical practice. At present, MRI results are interpreted
based upon subjective visual impressions of MRI images usually by a radiologist or
neurologist. In contrast, this method of interpretation is not utilized in research setting.
Instead, quantitative analyses of imaging results are conducted. Moreover, computer
programs that yield quantitative analyses of MRI data are not readily available outside of
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research settings, and clinicians are not receiving training on how to operate such
programs. For MRI models to be used, quantitative MRI data will be needed. This step
in the diagnostic process is important because this study has shown that a combination of
imaging and cognitive variables possess the greatest potential for increasing diagnostic
accuracy as it relates to MCI and dementia. Clearly, more widespread use of quantitative
imaging data in clinical practice is needed.
Conclusion
At present, the diagnostic criteria for MCI are varied and able to be interpreted
and implemented in different ways depending on the judgment of the clinician. Because
of this issue, a wide range of incidence, prevalence, and conversion rates are found in the
research literature. At its conceptual core, MCI is a term that was designed to describe
people in the earliest stages of cognitive decline secondary to dementia. Because of
issues inherent in these criteria, people with a wide range of non-dementing illnesses are
being diagnosed with a predementia syndrome. Thus, many people diagnosed with MCI
will have cognition and functional abilities that stay the same or even improve. In the
current study, it was proposed that the best way to improve MCI diagnostic criteria is to
put more of an emphasis on conversion to dementia. After all, if a person does not
convert to dementia, a diagnosis of a predementia syndrome seems rather unnecessary.
Moreover, by putting more of an emphasis on conversion when formulating diagnostic
criteria, questions raised by the patient and his/her family that relate to conversion
probabilities can be better answered.
In the current study, a model was constructed using MRI and cognitive variables that
was able to predict conversion from aMCI to AD with a high degree of accuracy (see
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Table 11). Using the equation derived from the model and its corresponding cut-score, a
patient could be told with 66% accuracy that he/she would convert to dementia within the
next year or with 99% accuracy that he/she would not convert to dementia within the next
year. The cut-score was selected to optimize sensitivity and identify a large majority of
people who would convert. However, different cutoffs could be selected for different
purposes, thereby, increasing the accuracy of a positive test result. Although equations
like this have the potential to drastically improve the way clinicians diagnose dementing
diseases, a number of issues concerning their application was illustrated in this paper
(e.g., quantitative MRI data is not readily available). Thus, a simple user-friendly model
was constructed that utilizes only information that can be obtained during a brief
evaluation (see Table 19). The resulting model was used to predict conversion with
modest accuracy. In addition, this model was also used to demonstrate the ease of use of
such an equation if an Excel spreadsheet and directions are included. Finally, a number
of other models were constructed to test the utility of different diagnostic systems. As
expected, the classification system with the best predictive validity utilized a cognitive
cutoff of 1.0 SD on Logical Memory – II and allowed for some level of functional
decline (i.e., scores ≤5 on the FAQ). The equation derived from this model included
variables representing functional ability, neurocognitive performance, and MRI
volumetric measures. In summary, these results clearly indicate that MCI diagnostic
criteria need to be better standardized, so clinical judgment can be taken out of the
equation.
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Table 1. MCI Diagnostic Criteria and Current Recommendations
Petersen Criteria

MCI-R Criteria

(Petersen et al., 1997)

(Winblad et al., 2004)

1. Presence of a subjective

1. Presence of a cognitive complaint from

memory complaint

either the patient and/or family member

2. Preserved general intellectual

2. Absence of dementia

functioning
3. Demonstration of a memory

3. Change from normal functioning

impairment by cognitive testing
4. Intact ability to perform ADLs

4. Decline in any area of cognitive
functioning

5. Absence of dementia

5. Preserved overall general functioning
but possibly with increasing difficulty in
the performance of ADLs

Note. MCI-R=mild cognitive impairment-revised
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Table 2. MCI-R Subtype and Etiology (Winblad et al., 2004.)
MCI-R Subtype

Etiology

amnestic-MCI (aMCI) (single

degenerative, vascular, metabolic, traumatic,

and multiple domains)
multiple domains, slightly
impaired-MCI (mdMCI)
single nonmemory domainMCI (snMCI)

psychiatric, other
degenerative, vascular, metabolic, traumatic,
psychiatric, other
degenerative, vascular, metabolic, traumatic,
psychiatric, other

Note. MCI =mild cognitive impairment, MCI-R=mild cognitive impairment-revised
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Table 3. Recommendations from the Alzheimer’s Group (Albert et al., 2011)
1. Cognitive concern reflecting a change in cognition reported by the patient
or informant or clinician (i.e., historical or observed evidence of decline over
time)
2. Objective evidence of impairment in one or more cognitive domains,
typically including memory (i.e., formal or bedside testing to establish level of
cognitive function in multiple domains)
3. Preservation of independence in functional abilities
4. Intact ability to perform ADLs
5. Not demented
6. Provide evidence of longitudinal decline in cognition, when feasible
Note. ADL=activities of daily living.
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Table 4. Biomarkers Under Examination for AD (Albert et al., 2011)
Biomarkers of Aβ deposition
CSF Aβ42
PET amyloid imaging
Biomarkers of neuronal injury
CSF tau/phosphorylated-tau
Hippocampal volume or medial temporal atrophy by volumetric measures
or visual rating
Rate of brain atrophy
FDG-PET imaging
SPECT perfusion imaging
Less well validated biomarkers: fMRI activation studies, resting BOLD
functional connectivity, MRI perfusion, MR spectroscopy, diffusion
tensor imaging, voxel-based and multivariate measures
Associated biochemical change
Inflammatory biomarkers (cytokines)
Oxidative stress (isoprostanes)
Other markers of synaptic damage and neurodegeneration such as cell death
Note. AD=Alzheimer’s disease, Aβ=beta-amyloid protein, CSF=cerebrospinal fluid,
PET=positron emission tomography, FDG=fluorodeoxyglucose, SPECT=single photon
emission tomography, MRI=magnetic resonance imaging, fMRI=functional magnetic
resonance imaging, BOLD=blood oxygen level-dependent, MR=magnetic resonance.
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Table 5. MCI Criteria Incorporating Biomarkers (Albert et al., 2011)
Diagnostic

Biomarker

category

probability of

Aβ (PET or CSF)

Neuronal Injury (tau,
FDG, sMRI)

AD etiology
MCI-core

Uninformative Conflicting/indetermiant/ Conflicting/indeterminant/
untested

untested

Intermediate

Positive, Untested

Untested, Positive

Highest

Positive

Positive

Lowest

Negative

Negative

clinical
criteria
MCI due
toAD—
Intermediate
likelihood
MCI due
toAD—
High
likelihood
MCI—
unlikely
due to AD

Note. AD=Alzheimer’s disease, Aβ=amyloid beta peptide, PET= positron emission
tomography, CSF=cerebrospinal fluid, FDG=fluorodeoxyglucose, sMRI=structural
magnetic resonance imaging.
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Table 6. Current Recommendations for Standardization of MCI Diagnostic Criteria
1. Intact general cognitive functioning as demonstrated by performance falling
greater than 1.0 SD above the mean on a test of general cognitive functioning (e.g.,
DRS-2)
2. Objective evidence of impairment in one or more cognitive domain as determined
by performance falling at 1.0 SD or lower below the mean and/or estimates of premorbid intelligence using age- and education-corrected scores on a
neuropsychological battery (normative data corrected for race should be used
whenever possible)
3. Preserved overall general functioning but possibly with increasing difficulty in the
performance of ADLs as determined by a measure of functional/ADL performance
(i.e., >80% on the SE-ADL scale)
4. Not demented
Note. MCI=mild cognitive impairment, SD=standard deviation, DRS=Dementia Rating
Scale, ADL=activities of daily living, SE-ADL=Schwab & England-ADLs.
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Table 7. Diagnostic Criteria for Classification Systems.
ADNI Criteria

Proposed

Proposed

Criteri

Criteri

a #1

a #2

Proposed Criteria #3

Normal

0

0

0

0

MCI

0.5

0.5

0.5

0.5

Mild AD

0.5 – 1.0

0.5 – 1.0

0.5 – 1.0

0.5 – 1.0

Normal

Above Cutoffs

>-1.0 SD

>-1.5 SD

>-1.5 SD from VIQ

MCI

Below Cutoffs

≤-1.0 SD

≤-1.5 SD

≤-1.5 SD from VIQ

Mild AD

Below Cutoffs

≤-1.0 SD

≤-1.5 SD

≤-1.5 SD from VIQ

Normal

24-30

24-30

24-30

24-30

MCI

24-30

24-30

24-30

24-30

Mild AD

20-26

20-26

20-26

20-26

Memory

Normal

None

None

None

None

Complaint

MCI

Yes

Yes

Yes

Yes

Mild AD

Yes

Yes

Yes

Yes

Normal

No changes

≤5 on FAQ

≤5 on FAQ

≤5 on FAQ

Essentially Normal ≤5 on FAQ

≤5 on FAQ

≤5 on FAQ

Decline

≥6 on FAQ

≥6 on FAQ

CDR

LM II

MMSE

Daily

Functioning MCI
Mild AD

≥6 on FAQ

Note. Differences between classification systems are highlighted. ADNI=Alzheimer’s
disease Neuroimaging Initiative, CDR=Clinical Dementia Rating, LM=Logical Memory,
MMSE= Mini-Mental Status Examination, MCI=mild cognitive impairment,
AD=Alzheimer’s disease, VIQ=verbal intelligence quotient, FAQ=Functional Activities
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Questionnaire.
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Table 8. Demographics for MCI Patients by Classification System.

Age

ADNI Criteria

Proposed

Proposed

Proposed

(n=397)

Criteria #1

Criteria #2

Criteria #3

(n=191)

(n=115)

(n=255)

73 (56-88, 7.3)

73.1 (66-86,

74 (56-89, 7.5)

75 (54-89, 7.3)

7.5)
Education

15.7 (4-20, 3.0)

14.6 (4-20, 3.3)

14.7 (4-20, 3.2)

15.5 (4-20, 3.1)

Female

141 (35.5%)

79 (41.6%)

53 (46.5%)

101 (39.6%)

Male

256 (64.5%)

111 (58.4%)

61 (53.5%)

154 (60.4%)

Caucasian

371 (93.5%)

178 (93.7%)

106 (93.0%)

241 (94.5%)

MMSE

27.0 (24-30,

26.6 (24-30,

26.3 (24-30,

27.0 (24-30,

1.8)

1.8)

1.8)

1.8)

Note. For Age, Education, and MMSE, mean (range, standard deviation); for female,
male, and Caucasian, number (percent). ADNI=Alzheimer’s disease Neuroimaging
Initiative; MMSE=Mini Mental Status Examination .
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Table 9. Neurocognitive Model using ADNI Backward Elimination Method
Variable

Mean

β

p

(Range)

Example

β X Example

Patient

Patient Score

Scores
4.95 (0-19)

-.177

<.001

0

0

Clock Score

4.20 (0-5)

-.273

.021

4

-1.092

AVLT Total

6.34 (0-15)

-.205

.012

5

-1.025

.46 (0-9)

.203

.072

0

0

-.82 (-2.67-

-.339

.015

-1.333

.452

2.08 (0-15)

.112

.027

0

0

.41 (-2.67-2.67)

.219

.080

.333

.073

15.82 (2-60)

-.064

.032

16

-1.024

1.12 (0-13)

.176

.005

3

.528

Logical Memory
– II

Recall Trial 3
AVLT Total
Intrusion
Trial 5
AVLT
Recognition

1.33)

Z score
AVLT
Recognition
Errors
Digit Span Z
Score
Animal Naming
Total
Animal Naming

89

Perseverations
Trails A

43.93 (15-296)

.014

.001

39

.546

BNT Total

2.65 (0-30)

-.109

.003

4

-.436

Stimulus Cues
Constant

-.073

Total

-.073
-2.078

Note. Mean (Range)=mean and range. β X Example Patient Score refers to multiplying
unstandardized beta weight and patient score on associated variable. Total refers to sum
of β X Actual Score. β=unstandardized beta weight, Actual Score=patient score on
variable, ADNI=Alzheimer’s disease Neuroimaging Initiative, AVLT=Rey Auditory
Verbal Learning Test, BNT=Boston Naming Test.
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Table 10. Imaging Model using ADNI Backward Elimination Method
Variable

Mean (Range)

β

p

Example β X Example
Patient

Patient Score

Score
Cumulative

983 (885-1036)

-.063

<.001 991.279

-62.45

1799 (816-2805)

-.002

.001

1959.830 -3.92

.282 (.087-.488)

19.218

.003

.374

7.18

.432 (.061-.743)

-19.653

.001

.528

-10.38

.397 (.114-.577)

12.989

.058

.446

5.80

.45 (.13-.76)

11.335

.034

.527

6.0

.333 (.120-.557)

-15.869

.003

.366

-5.80

Temporal Lobe
Atrophy
Left
Hippocampus
Volume
Right
Precentral Grey
Matter
Right Frontal
Mid Orbital
Grey Matter
Left Frontal
Inferior Orbital
Grey Matter
Left Frontal
Medial Orbital
Grey Matter
Right Posterior
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Cingulum
Grey Matter
Right Amygdala .62 (.16-.86)

-7.958

.024

.741

-5.90

.30 (.11-.55)

-6.119

.103

.387

-2.37

.423 (.151-.651)

-14.076

.003

.450

-6.33

.48 (.18-.71)

14.472

.001

.591

8.55

Grey Matter
Left Superior
Parietal Grey
Matter
Left Superior
Temporal Grey
Matter
Right
Cerebellum
Grey
Matter
Constant

68.101

Total

68.101
-1.519

Note. Mean (Range)=mean and range for MCI patients. β X Example Patient Score refers
to multiplying unstandardized beta weight and patient score on associated variable, Total
refers to sum of β X Actual Score. Units of measurement for imaging variables are listed
in mm3.β=unstandardized beta weight, Actual Score=patient score on variable,
ADNI=Alzheimer’s disease Neuroimaging Initiative.
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Table 11. Final Model using ADNI Criteria, Hand Selected Method
Variable

Mean (Range)

β

p

Example β X Example
Patient

Patient Score

Score
2.67 (0-15)

-.392

.109

2

-.784

.46 (0-7)

1.006

.003

0

0

1.12 (0-13)

.287

.022

1

.287

2.65 (0-30)

-.260

.006

5

-1.3

ADAS-Cog Total 18.7 (0-30)

.115

.030

24

2.76

Logical Memory 4.95 (0-19)

-.052

.639

7

-.364

AVLT Delayed
Total
AVLT Total
Intrusions
Trial 2
Animal Naming
Perseverations
BNT Total
Semantic
Cues

– II
CDR Judgment

.390 (0-2)

3.136

.014

.5

1.568

Cumulative

983 (885-1036) -.079

.003

975.789

-77.087

.001

.342

11.1

Temporal
Lobe Atrophy
Right Precentral .282 (.087-.488) 32.456
Grey Matter
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Front Mid

.432 (.061-.743) -26.645

.003

.467

-12.443

.397 (.114-.577) 21.584

.064

.395

8.526

.333 (.120-.557) -13.578

.078

.376

-5.105

.423 (.151-.651) -13.125

.101

.427

-5.604

Orbital Right
Grey Matter
Front Inferior
Orbital Left
Grey Matter
Posterior Right
Cingulum
Grey Matter
Left Superior
Temporal
Grey Matter
Constant

76.564

.004

Total Equation

76.564
-1.882

Score
Note. See Statistical Analyses section for description of Hand Selected Method. Mean
(Range)=mean and range of MCI patients. β X Example Patient Score refers to
multiplying unstandardized beta weight and patient score on associated variable, Total
refers to sum of β X Actual Score. Units of measurement for imaging variables are listed
in mm3. β=unstandardized beta weight, Actual Score=patient score on variable,
ADNI=Alzheimer’s disease Neuroimaging Initiative, AVLT=Rey Auditory Verbal
Learning Test, BNT=Boston Naming Test, ADAS-Cog=Alzheimer’s disease Assessment
Scale-Cognition, CDR=Clinical Dementia Rating.
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Table 12. Number and Percentage of Patients Identified as Normal, MCI, and Mild AD
and Converting from MCI to dementia.
ADNI Criteria Proposed
Proposed
Proposed
Criteria #1

Criteria #2

Criteria #3

Normal

229 (27.9)

229 (27.9)

230 (28.0)

230 (28.0)

MCI

397 (48.4)

191 (23.3)

115 (14.0)

255 (31.1)

Mild AD

192 (23.4)

201 (24.5)

183 (22.3)

191 (23.3)

Unclassified

0

197 (24.1)

290 (35.5)

142 (17.4)

Conversions

164 (41.3)

47 (25.0)

42 (36.5)

61 (23.9)

Note. For each cell, mean (%). Conversions=patients converting from MCI to dementia.
Proposed Criteria #1 = ≤-1 SD on Logical Memory – II and <6 on the FAQ, Proposed
Criteria #2 = ≤-1.5 SD on Logical Memory – II and <6 on the FAQ, Proposed Criteria #3
= ≤-1.5 SD in relation to VIQ on Logical Memory – II and <6 on the FAQ (See Table 7
for detailed description). ADNI=Alzheimer’s disease neuroimaging initiative, MCI=mild
cognitive impairment, AD=Alzheimer’s disease, FAQ=Functional Activities
Questionnaire, VIQ=verbal intelligence.
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Table 13. Final Model using ADNI Criteria, Backward Elimination Method
Variable

Mean (Range)

β

p

Example β X Example
Patient

Patient Score

Score
CDR Judgment

.390 (0-2)

Logical Memory –II 4.95 (0-19)

2.544

.019 .5

.05

-.305

.003 0

0

Digit Span z score

.414 (-2.67-2.67) .344

.210 0

0

Animal Naming

15.82 (2-60)

-.066

.157 15

-.99

1.12 (0-13)

.246

.034 2

.492

-.265

.002 7

-1.855

983 (885-1036)

-.085

.001 993.919

-84.48

2.417 (1.536-

-3.202

.020 2.253

-7.22

.282 (.087-.488)

27.615

.001 .348

9.62

.432 (.061-.743)

-18.282

.007 .590

-10.78

2.093 (1.331-

3.968

.116 2.40

9.52

Total Correct
Animal Naming
Perseverations
BNT Stimulus Cues 2.65 (0-30)
Cumulative
Temporal Lobe
Atrophy
Middle Left
Temporal Grey

2.951)

Matter
Right Precentral
Grey Matter
Front Mid Orbital
Right Grey Matter
Total Intracranial
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Volume

2.513)

Constant

80.697

Total Equation

80.697
-4.946

Score
Note. Mean (Range)=mean and range of MCI patients. β X Example Patient Score refers
to multiplying unstandardized beta weight and patient score on associated variable, Total
refers to sum of β X Actual Score. Units of measurement for imaging variables are listed
in mm3. β=unstandardized beta weight, Actual Score=patient score on variable,
ADNI=Alzheimer’s disease Neuroimaging Initiative, BNT=Boston Naming Test,
CDR=Clinical Dementia Rating.
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Table 14. Final Model using Proposed Criteria #1(Model #1).
Variable

Mean (Range) β

p

Example β X Example
Patient

Patient Score

Score
CDR Judgment

.366 (0-1)

5.063

.016

FAQ

1.85 (0-5)

1.172

<.001 5

5.86

-1.748

<.001 8

-13.984

6.465

.001

-1.0

-6.465

Logical Memory I Total 5.91 (0-14)

0

0

Logical Memory I z

-1.43 (-2.67-

score

.67)

Clock Score

4.15 (1-5)

-.969

.033

2

-1.938

Clock Copy Score

4.69 (2-5)

5.783

<.001 5

28.915

AVLT Total Intrusion

1.11 (0-7)

.810

.011

.810

Digit Span Total

14.31 (5-24)

2.762

<.001 10

27.62

Digit Span Forward

8.19 (1-12)

-3.773

.001

6

-22.638

6.50 (3-8)

1.603

.067

5

8.015

4.53 (2-7)

-4.530

.001

4

-18.12

1

Trial 6

Total
Digit Span Forward
Length
Digit Span Backward
Length
Trails A

42.33 (17-150) .071

.028

42

2.928

Trails B

123.81 (40-

.001

68

-5.1

-.075

98

300)
Trails A – B z score

-.65 (-14.32-

-1.756

.001

1.191

-2.091

.619

.001

20

12.38

1.85)
ADAS-Cog Total

20.29 (3.3335.67)

Right Precental Grey

.25 (.09-.38)

121.155 <.001 .150

18.219

.31 (.11-.51)

-43.195

.021

.222

-9.586

.35 (.15-.61)

83.692

<.001 .271

22.707

.43 (.24-.62)

-70.822

<.001 .355

-25.108

.43 (.19-.72)

-15.490

.017

.285

-4.421

.13 (.01-.60)

24.151

<.001 .428

10.342

.43 (.17-.67)

-64.065

.006

.348

-22.314

.44 (.19-.65)

52.943

.008

.356

18.871

Matter
Right Inferior Frontal
Gyrus Grey Matter
Left Rolandic
Operculum Grey
Matter
Right Mid Cingulum
Grey Matter
Right Hippocampus
Grey Matter
Right Pallidum Grey
Matter
Right Mid Temporal
Grey Matter
Left Mid Temporal
Grey Matter
Constant

-29.464
99

-29.464

Total Equation Score

-4.562

Note. Mean (Range)=mean and range of MCI patients. β X Example Patient Score refers
to multiplying unstandardized beta weight and patient score on associated variable, Total
refers to sum of β X Actual Score. Units of measurement for imaging variables are listed
in mm3. β=unstandardized beta weight, Actual Score=patient score on variable,
CDR=Clinical Dementia Rating, AVLT=Auditory Verbal Learning Test, ADASCOG=Alzheimer’s disease Assessment Scale-Cognitive, FAQ=Functional Activities
Questionnaire.
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Table 15. Final Model using Proposed Criteria #2 (Model #2).
Variable

Mean

β

(Range)

p

Example β X Example
Patient

Patient Score

Score
FAQ

2.18 (0-5)

.873

.008 3

2.619

Clock Copy Score

4.70 (3-5)

1.737

.130 5

8.585

.002 -1.667

3.358

AVLT Initial Recall z score -.35 (-2.67- -2.015
2.33)
AVLT Total Errors Initial

.52 (0-5)

1.164

.021 1

1.164

1.39 (0-9)

.577

.009 0

0

42.92 (18-

.054

.026 55

2.97

.135 -.277

-.128

.023 1

-.412

.34 (.14-.50) -50.114

.004 .304

-15.241

.28 (.10-.45) -47.125

.002 .282

-13.304

.41 (.22-.60) 45.656

.001 .373

17.014

Recall
Animal Naming
Perseverations
Trails A score

150)
Trails A – B z score

-.85 (-12.44- .463
1.8)

BNT Phonemic Cue

2.84 (0-14)

-.412

Correct
Left Posterior Cingulum
Grey Matter
Left Superior Occipital
Grey Matter
Left Supramarginal Gyrus
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Grey Matter
Right Central

.25 (.10-.46) 37.009

.004 .210

7.780

Parahippocampal
Gyrus
Constant

-21.501

Total Equation Score

-21.501
-7.096

Note. Mean (Range)=mean and range for MCI patients. β X Example Patient Score refers
to multiplying unstandardized beta weight and patient score on associated variable, Total
refers to sum of β X Actual Score. Units of measurement for imaging variables are listed
in mm3. β=unstandardized beta weight, Actual Score=patient score on variable,
BNT=Boston Naming Test, FAQ=Functional Activities Questionnaire, AVLT=Auditory
Verbal Learning Test.
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Table 16. Final Model using Proposed Criteria #3 (Model #3).
Variable

Mean (Range)

β

p

Example β X Example
Patient

Patient Score

Score
FAQ

1.85 (0-5)

.371

.002

3

1.113

.125

.001

27

3.375

3311 (1649-4835)

-.001

.003

2676

-2.676

.35 (.07-.61)

-10.02

.007

.332

-3.329

.34 (.16-.56)

17.358 <.001 .282

4.898

.36 (.15-.60)

8.235

2.614

ADAS-Cog Total 18.73 (3-35.6)
Right
Hippocampal
Volume
Right Mid
Frontal Grey
Matter
Left Heschl’s
Gyrus Grey
Matter
Right Inferior

.098

.317

Parietal Grey
Matter
Constant

-8.562

Total Equation

-8.562
-2.567

Score
Note. Mean (Range)=mean and range of MCI patients. β X Example Patient Score refers
to multiplying unstandardized beta weight and patient score on associated variable, Total
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refers to sum of β X Actual Score. Units of measurement for imaging variables are listed
in mm3. β=unstandardized beta weight, Actual Score=patient score on variable,
FAQ=Functional Activities Questionnaire, ADAS-COG=Alzheimer’s disease
Assessment Scale-Cognitive.
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Table 17. Performance of Models across Classification System (β, p).
ADNI

Proposed

Proposed

criteria #1
ADNI hand

6.113,

selected model

<.001

ADNI

2.330,

backward

.157

criteria #2

Proposed
criteria #3

6.563, .020

10.123, .019

2.782, .165

2.352, .393

-5.335, .316

2.380, .289

3.199, <.001

9.190, .051

3.558, .002

-2.727, .417

7.862, <.001

.397, .851

5.426, .087

-7.532, .267

6.271, <.001

elimination
model
Model #1

6.032,
<.001

Model #2

3.026,
.071

Model #3

.939, .590

Note. For each cell, unstandardized beta, p value. ADNI=Alzheimer’s disease
Neuroimaging Initiative, β=unstandardized beta.

105

Table 18. Performance of Models across Classification Systems (Pseudo R2, AUC).
ADNI

Proposed

Proposed criteria

Proposed criteria

criteria #1

#2

#3

.61, .93

.40, .86

.51, .89

.35, .81

.50, .91

.31, .82

.33, .81

.26, .76

Model #1

.39, .88

.74, .97

.62, .94

.47, .89

Model #2

.22, .81

.39, .87

.77, .97

.25, .80

Model #3

.23, .82

.35, .86

.31, .83

.41, .88

ADNI hand
selected model
ADNI
backward
elimination
model

Note. For each cell, pseudo R2, AUC. Yellow highlighting indicates the pseudo-R2 and
AUC of each model in relation to the Proposed Criteria from which they were derived.
Blue highlighting indicates the best and red highlighting indicates the worst pseudo-R2
and AUC of a model in relation to a validation sample/Proposed Criteria from which it
was not derived. ADNI=Alzheimer’s disease Neuroimaging Initiative, AUC=area under
the curve.
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Table 19. User-Friendly Model
Variable

Mean (Range)

β

p

FAQ

4.29 (0-28)

.083

<.001

-.158

.002

Logical Memory – II 4.95 (0-19)
Clock Score

4.20 (0-5)

-.176

.133

AVLT Delay Total

2.67 (0-15)

-.167

.035

Trails A

43.93 (15-296)

.010

.037

ADAS-Cog Total

18.72 (0-67)

.034

.129

-3.456

Constant

Note. Mean (Range)=mean and range of MCI patients. β=unstandardized beta weight,
FAQ=Functional Activities Questionnaire, ADAS-Cog=Alzheimer’s disease Assessment
Scale-Cognitive.
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Appendix A: Model and Equation Derived from Neurocognitive Performances
The resulting equation constructed from neurocognitive performance is as follows
(see Table 9):
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Examples may be useful for those not familiar with regression-based models (see
Table 9). For this sample of people with MCI, the following means were observed: 4.45
on Logical Memory II, 4.20 on Clock Drawing, 6.34 on AVLT Trial 3, 5.46 on AVLT
Total Intrusions for Trial 5, -0.82 for AVLT Recognition z-score, 2.08 for AVLT
Recognition Errors, 0.41 for Digit Span z-score, 15.82 on Animal Naming, 1.12 on
Animal Naming Total Perseverations, 43.93 on Trails A, and 2.65 on BNT Stimulus
Cues. Using average neurocognitive performances and the constant obtained for this
model (-0.073), this sample of people with MCI would have an overall score of -2.08—
above the clinical cutoff of -2.32. This means the sample as a whole is demonstrating an
increased risk of conversion.
However, most applications of this model will likely occur at the individual level,
and one such example can be found in Table 9. For this example (i.e., -0.073 – [0.177*0]
– [0.273*4] – [0.205*5] + [0.203*0] + [0.339*1.333] + [0.112*0] + [0.219*0.333] –
[0.064*16] + [0.176*3] + [0.014*39] – [0.109*4] = -2.078), the obtained score also lies
above the clinical cutoff of -2.32, so conversion within a 2-year period is likely. For a
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person who scored 8.0 on Logical Memory II, 5.0 on Clock Drawing, 7.0 on AVLT Trial
3, 2.0 on AVLT Total Intrusions for Trial 5, 0.09 for AVLT Recognition z-score, 1.0 for
AVLT Recognition Errors, 0.41 for Digit Span z-score, 17.0 on Animal Naming, 1.0 on
Animal Naming Total Perseverations, 34.0 on Trails A, and 2.0 on BNT Stimulus Cues
the equation based on neuropsychological performance would be as follows: -0.073 –
[0.177*8] – [0.273*5] – [0.205*7] + [0.203*2] + [0.339*0.09] + [0.112*1] +
[0.219*0.41] – [0.064*17] + [0.176*1] + [0.014*34] – [0.109*2] = -4.3047. This
obtained scores lies well below the clinical cutoff of -2.32, so conversion over a one-year
period is unlikely. For those interested, an Excel spreadsheet and instructions for use can
be obtained from the first author of this study that will calculate this equation.
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Appendix B: Model and Equation Derived from Neuroimaging Data
The resulting equation constructed from imaging variables is as follows (see
Table 9):

(

[

(

])

(

)
)

)

(

(

)
)

(
(

)

(
(

)
)

(

)
)

(
(

)
Examples of this regression-based model are provided in Table 10. For this sample of

people with MCI the following means were observed: cumulative temporal lobe atrophy
of 983 mm3, left hippocampus volume of 1799 mm3, right precentral grey matter of 0.282
mm3, right frontal mid orbital grey matter of 0.432 mm3, left frontal inferior orbital grey
matter of 0.397 mm3, left frontal medial orbital grey matter of 0.453 mm3, right posterior
cingulum grey matter of 0.333 mm3, right amygdala grey matter of 0.62 mm3, left
superior parietal grey matter of 0.30 mm3, left superior temporal grey matter of 0.432
mm3, right cerebellum grey matter of 0.48 mm3. Using these averages and the constant
obtained for this model (68.101), this sample of people with MCI would have an overall
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score of -1.301—above the clinical cutoff of -2.04. This means the sample as a whole is
demonstrating an increased risk of conversion. However, as with the neurocognitive
model, most applications will likely occur at the individual level, and one such example
can be found in Table 10. For this example (i.e., 68.101 – [0.063*991.279] –
[0.002*1959.83] + [19.218*0.374] – [19.653*0.528] + [12.989*0.446] + [11.335*0.527]
– [15.869*0.366] – [7.958*0.741] – [6.119*0.387] – [14.076*0.450] + [14.472*0.591] =
-1.519), the obtained score also lies above the clinical cutoff, so conversion within a 2year period is likely. For those interested, an Excel spreadsheet and instructions for use
can be obtained from the first author of this study that will calculate this equation.
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Graduate Teaching Assistant (TA) for Psychology 201: Introduction to Psychology (Fall
2012).
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